Novel genetic armor

By expressing the recombinant IL-15 receptor β subunit and introducing a lysable peptide linker, the response of γδ T cells to IL-15 was enhanced, and the problem of reduced response of CAR+ cells to IL-15 was solved, and the proliferation and survival of cells was improved. Ability, suitable for immunotherapy.

CN118973609APending Publication Date: 2024-11-15GAMMADELTA THERAPEUTICS LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202380032666.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-02-01
Filing Date
2023-04-04
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Traditional chimeric antigen receptor (CAR) armor attempts to improve the durability and growth of CAR+ cells by making cells express IL-15, but CAR+γδT cells are less responsive to IL-15, resulting in less effective results in immunotherapy. good.

Method used

The forward IL-15 signaling loop is introduced by expressing the recombinant IL-15 receptor beta subunit (IL-15Rβ) and/or fragments thereof, enhancing the response of CAR+ cells to IL-15, including in IL-15Rβ and IL A cleavable peptide linker, such as 2A peptide, is added between -15 or a variant thereof, to achieve signaling.

Benefits of technology

It improves the sensitivity and responsiveness of γδT cells to IL-15, enhances the proliferation and survival ability of cells, provides more effective cytotoxicity, and is suitable for various immunotherapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005072036020000271
    Figure BDA0005072036020000271
  • Figure BDA0005072036020000281
    Figure BDA0005072036020000281
  • Figure BDA0005072036020000291
    Figure BDA0005072036020000291
Patent Text Reader

Abstract

The present disclosure provides compositions and methods for effecting engineering of gamma delta T cells (e.g., v delta 1 T cells and v delta 2 T cells) with IL-15 receptor beta subunits (IL-15R beta) to restore IL-15 responsiveness, e.g., by transduction with a viral vector. Further provided are populations of engineered gamma delta T cells and methods of using the same.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This PCT application claims the benefit of priority to U.S. Provisional Application No. 63 / 327,230, filed on April 4, 2022; U.S. Provisional Application No. 63 / 371,860, filed on August 18, 2022; and U.S. Provisional Application No. 63 / 482,755, filed on February 1, 2023, each of which is incorporated herein by reference in its entirety.

[0003] Citations of Sequence Listings Submitted Electronically via EFS-WEB

[0004] The contents of the sequence listing of the electronically submitted ASCII text file (Name: 3817_170PC03_Seqlisting_ST26; Size: 39,258 bytes; and Creation Date: April 3, 2023) submitted with this application are incorporated herein by reference in its entirety. Technical Field

[0005] Traditional chimeric antigen receptor (CAR) armor attempts to improve the persistence, growth or other properties of CAR+ cells by causing the cells to also express IL-15 (secreted or membrane-bound). CAR+γδT cells co-expressing IL-15 in the same construct or separately will reduce the responsiveness of the cells to IL-15. Therefore, new compositions and methods are needed to reprogram γδT cells to provide responsiveness to IL-15 to adapt these cells to various immunotherapies. Background Art

[0006] Growing interest in T cell immunotherapy for cancer has focused on the apparent ability of engineered T cells as a therapeutic moiety. Gamma delta (γδ) T cells represent a subset of T cells that express a unique, defining γδ T cell receptor (TCR) on their surface. This TCR consists of one gamma (γ) and one delta (δ) chain. Human γδ T cells can be broadly classified into one or two types: peripheral blood-resident γδ T cells and non-hematopoietic tissue-resident γδ T cells. Most blood-resident γδ T cells express the Vδ2 TCR, while this phenomenon is less common in tissue-resident γδ T cells, which more frequently use Vδ1 and / or other Vδ chains.

[0007] IL-15 is a cytokine and T cell growth factor that binds to and signals through a receptor complex comprising an IL-15 receptor β subunit (IL-15Rβ, also known as IL-2Rβ), an IL-15 receptor α subunit (IL-15Rα), and a common γ chain. IL-15 is typically secreted by phagocytes after infection and induces the proliferation of certain immune cells (e.g., natural killer cells), which then proceed to kill infected cells. Traditional chimeric antigen receptor (CAR) armor attempts to improve the persistence, growth, or other properties of CAR+ cells by causing the cells to also express IL-15 (secreted or membrane-bound). CAR+Vδ1T cells co-expressing IL-15 in the same construct or separately reduce the responsiveness of the cells to IL-15. Therefore, new compositions and methods are needed to reprogram γδT cells to provide responsiveness to IL-15 so that these cells can adapt to various immunotherapies. Summary of the invention

[0008] In one aspect, the invention provides a γδ T cell expressing a recombinant IL-15 receptor β subunit (IL-15Rβ) (e.g., wherein the IL-15Rβ is expressed without the co-expression of a recombinant IL-15 receptor α subunit (IL-15Rα) (e.g., without the co-expression of a recombinant IL-15 receptor α subunit (IL-15Rα)), wherein the N-terminus of the IL-15Rα or a fragment thereof is tethered to the C-terminus of IL-15 or a variant thereof).

[0009] In some embodiments, the γδ T cells further express recombinant IL-15 receptor α subunit (IL-15Rα) or a fragment thereof.

[0010] In some embodiments, the IL-15Rα or fragment thereof is tethered to IL-15 or a variant thereof. In some embodiments, the C-terminus of the IL-15Rα or fragment thereof is tethered to the N-terminus of the IL-15 or a variant thereof. In some embodiments, the N-terminus of the IL-15Rα or fragment thereof is tethered to the C-terminus of the IL-15 or a variant thereof.

[0011] In some embodiments, the IL-15Rβ and the IL-15Rα or a fragment thereof are expressed in tandem. The IL-15Rβ and the IL-15Rα or a fragment thereof may include a linker therebetween. The linker may include a cleavable peptide. The cleavable peptide may be, for example, a self-cleaving peptide, such as a 2A peptide. In some embodiments, the 2A peptide is a foot-and-mouth disease virus 182A (F2A) peptide, an equine rhinitis A virus 2A (E2A) peptide, a porcine Teschovirus-12A (P2A) peptide, or a thosea asigna virus 2A (T2A) peptide.

[0012] In some embodiments, the γδ T cells further express a chimeric antigen receptor (CAR). The CAR may lack an intracellular signaling domain.

[0013] In some embodiments, the γδ T cells lack an endogenous gene encoding IL-15.

[0014] In some embodiments, the γδ T cells further express secreted IL-15 or a variant thereof.

[0015] In another aspect, the present invention provides a γδ T cell expressing recombinant IL-15Rβ and recombinant IL-15 or a variant thereof.

[0016] In some embodiments, the IL-15Rβ and the IL-15 or its variant are expressed in tandem. The IL-15Rβ and the IL-15 or its variant may include a linker therebetween. The linker may include a cleavable peptide. The cleavable peptide may be, for example, a self-cleaving peptide, such as a 2A peptide. In some embodiments, the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide, or a T2A peptide.

[0017] In some embodiments, the γδT cells further express recombinant IL-15Rα or a fragment thereof. The fragment of the IL-15Rα may include, for example, a soluble fragment. The soluble fragment may include, for example, a sushi domain. The sushi domain may be attached to an Fc domain. In some embodiments, the IL-15Rα or a fragment thereof is tethered to the IL-15 or a variant thereof. In some embodiments, the C-terminus of the IL-15Rα or a fragment thereof is tethered to the N-terminus of the IL-15 or a variant thereof. In some embodiments, the N-terminus of the IL-15Rα or a fragment thereof is tethered to the C-terminus of the IL-15 or a variant thereof.

[0018] In some embodiments, the IL-15Rβ and the IL-15Rα or a fragment thereof are expressed in tandem. For example, the IL-15Rβ and the IL-15Rα or a fragment thereof may include a second linker therebetween. The second linker may include a cleavable peptide. The cleavable peptide may be, for example, a self-cleaving peptide, such as a 2A peptide. In some embodiments, the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide, or a T2A peptide.

[0019] In some embodiments, the IL-15Rβ, the IL-15 or a variant thereof, and the recombinant IL-15Rα or a fragment thereof are expressed in tandem.

[0020] In some embodiments, the γδ T cells further express a CAR. The CAR may lack an intracellular signaling domain.

[0021] In some embodiments, the γδ T cells lack an endogenous gene encoding IL-15.

[0022] In another aspect, the present invention provides an isolated γδT cell population, wherein at least 10% (e.g., at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97% or 99%) of the γδT cell population expresses recombinant IL-15Rβ. In some embodiments, at least 50% of the γδT cell population expresses the recombinant IL-15Rβ.

[0023] In some embodiments, the isolated population of γδ T cells further expresses recombinant IL-15Rα or a fragment thereof.

[0024] In some embodiments, the IL-15Rα or fragment thereof is tethered to IL-15 or a variant thereof. In some embodiments, the C-terminus of the IL-15Rα or fragment thereof is tethered to the N-terminus of the IL-15 or a variant thereof. In some embodiments, the N-terminus of the IL-15Rα or fragment thereof is tethered to the C-terminus of the IL-15 or a variant thereof.

[0025] In some embodiments, the IL-15Rβ and the IL-15Rα or a fragment thereof are expressed in tandem. The IL-15Rβ and the IL-15Rα or a fragment thereof may include a linker therebetween. The linker may include a cleavable peptide. The cleavable peptide may be, for example, a self-cleaving peptide, such as a 2A peptide. In some embodiments, the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide, or a T2A peptide.

[0026] In some embodiments, the isolated γδ T cell population further expresses a CAR. The CAR may lack an intracellular signaling domain.

[0027] In some embodiments, the isolated population of γδ T cells lacks an endogenous gene encoding IL-15.

[0028] In some embodiments, the isolated population of γδ T cells further express secreted IL-15 or a variant thereof.

[0029] In another aspect, the present invention provides an isolated γδT cell population, wherein at least 10% (e.g., at least 20%, 30%, 40%, 50% 60%, 70%, 80%, 90%, 95%, 97% or 99%) of the γδT cell population expresses recombinant IL-15Rβ and IL-15 or a variant thereof. In some embodiments, at least 50% of the γδT cell population expresses recombinant IL-15Rβ and IL-15 or a variant thereof.

[0030] In some embodiments, the IL-15Rβ and the IL-15 or its variant are expressed in tandem. For example, the IL-15Rβ and the IL-15 receptor or its variant may include a linker therebetween. The linker may include a cleavable peptide. The cleavable peptide may be, for example, a self-cleaving peptide, such as a 2A peptide. In some embodiments, the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide, or a T2A peptide.

[0031] In some embodiments, the isolated γδT cell population further expresses recombinant IL-15Rα or a fragment thereof. The fragment of the IL-15Rα may include, for example, a soluble fragment. The soluble fragment may include, for example, a sushi domain. The sushi domain may be attached to an Fc domain. In some embodiments, the IL-15Rα or a fragment thereof is tethered to the IL-15 or a variant thereof. In some embodiments, the C-terminus of the IL-15Rα or a fragment thereof is tethered to the N-terminus of the IL-15 or a variant thereof. In some embodiments, the N-terminus of the IL-15Rα or a fragment thereof is tethered to the C-terminus of the IL-15 or a variant thereof.

[0032] In some embodiments, the IL-15Rβ and the IL-15Rα or a fragment thereof are expressed in tandem. For example, the IL-15Rβ and the IL-15Rα or a fragment thereof may include a second linker therebetween. For example, the IL-15Rβ and the IL-15Rα or a fragment thereof may include a second linker therebetween. The second linker may include a cleavable peptide. The cleavable peptide may be, for example, a self-cleaving peptide, such as a 2A peptide. In some embodiments, the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide, or a T2A peptide.

[0033] In some embodiments, the IL-15Rβ, the IL-15 or a variant thereof, and the recombinant IL-15Rα or a fragment thereof are expressed in tandem.

[0034] In some embodiments, the isolated γδ T cell population further expresses a CAR. The CAR may lack an intracellular signaling domain.

[0035] In some embodiments, the isolated population of γδ T cells lacks an endogenous gene encoding IL-15.

[0036] In another aspect, the present invention provides a method for producing a γδT cell population expressing recombinant IL-15Rβ. The method comprises (a) providing a γδT cell population; and (b) transducing the γδT cell population with a polynucleotide encoding IL-15Rβ, thereby producing the γδT cell population expressing the recombinant IL-15Rβ.

[0037] In some embodiments, the polynucleotide comprises an IRES operably linked to the IL-15Rβ.

[0038] In some embodiments, the method further comprises transducing the initial γδT cell population with a polynucleotide encoding IL-15Rα or a fragment thereof. In some embodiments, the IL-15Rα or a fragment thereof is tethered to IL-15 or a variant thereof. In some embodiments, the C-terminus of the IL-15Rα or a fragment thereof is tethered to the N-terminus of the IL-15 or a variant thereof. In some embodiments, the N-terminus of the IL-15Rα or a fragment thereof is tethered to the C-terminus of the IL-15 or a variant thereof.

[0039] In some embodiments, the polynucleotide encodes the IL-15Rβ and the IL-15Rα in series. The polynucleotide may include a linker between the IL-15Rβ and the IL-15Rα. The linker may encode a cleavable peptide or include an IRES. The cleavable peptide may be, for example, a self-cleaving peptide, such as a 2A peptide. In some embodiments, the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide, or a T2A peptide.

[0040] In some embodiments, the method further comprises transducing cells with a polynucleotide encoding a CAR. In some embodiments, the polynucleotide encodes the CAR and the IL-15Rβ in series. For example, the polynucleotide may include a joint between the CAR and the IL-15Rβ. The joint may encode a cleavable peptide or include an IRES. The cleavable peptide may be, for example, a self-cleaving peptide, such as a 2A peptide. In some embodiments, the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide, or a T2A peptide.

[0041] In another aspect, the present invention provides a method for producing a γδT cell population expressing recombinant IL-15Rβ and IL-15 or a variant thereof. The method comprises (a) providing a γδT cell population; (b) transducing the γδT cell population with a polynucleotide encoding the IL-15Rβ; and (c) transducing the γδT cell population with a polynucleotide encoding the IL-15 or a variant thereof, thereby producing a γδT cell population expressing the recombinant IL-15Rβ and the IL-15 or a variant thereof.

[0042] In some embodiments, the polynucleotide comprises an IRES operably linked to the IL-15Rβ and / or the IL-15 or variant thereof.

[0043] In some embodiments, the polynucleotide encodes the IL-15Rβ and the IL-15 or its variant in series. For example, the polynucleotide may include a linker between the IL-15Rβ and the IL-15 or its variant. The linker may encode a cleavable peptide or include an IRES. The cleavable peptide may be, for example, a self-cleaving peptide, such as a 2A peptide. In some embodiments, the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide, or a T2A peptide.

[0044] In some embodiments, the method further comprises transducing the initial γδT cell population with a polynucleotide encoding IL-15Rα or a fragment thereof. The fragment of IL-15Rα may include a soluble fragment. For example, the soluble fragment may include a sushi domain. In some embodiments, the sushi domain is attached to an Fc domain.

[0045] In some embodiments, the IL-15Rα or a fragment thereof is tethered to the IL-15 or a variant thereof. In some embodiments, the C-terminus of the IL-15Rα or a fragment thereof is tethered to the N-terminus of the IL-15 or a variant thereof. In some embodiments, the N-terminus of the IL-15Rα or a fragment thereof is tethered to the C-terminus of the IL-15 or a variant thereof.

[0046] In some embodiments, the polynucleotide encodes the IL-15Rβ and the IL-15Rα in tandem.

[0047] In some embodiments, the polynucleotide includes a second linker between the IL-15Rβ and the IL-15Rα. The second linker may encode a cleavable peptide or include an IRES. The cleavable peptide may be, for example, a self-cleaving peptide, such as a 2A peptide. In some embodiments, the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide, or a T2A peptide.

[0048] In some embodiments, the polynucleotide encodes the IL-15Rβ, the IL-15 or a variant thereof, and the recombinant IL-15Rα or a fragment thereof in tandem.

[0049] In some embodiments, the method further comprises transducing cells with a polynucleotide encoding a CAR. The polynucleotide may encode the CAR and the IL-15Rβ in series. For example, the polynucleotide may include a joint between the CAR and the IL-15Rβ. The joint may encode a cleavable peptide or include an IRES. The cleavable peptide may be, for example, a self-cleaving peptide, such as a 2A peptide. In some embodiments, the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide, or a T2A peptide.

[0050] In some embodiments of any of the methods described herein, the method includes providing a vector comprising the polynucleotide. The vector can be, for example, a viral vector. The viral vector can be, for example, a Retroviridae virus, an adenovirus, a parvovirus, a coronavirus, a rhabdovirus, a paramyxovirus, a picornavirus, an alphavirus, a herpes virus, or a poxvirus.

[0051] In some embodiments, the parvoviral viral vector is an AAV vector.

[0052] In some embodiments, the viral vector is a Retroviridae viral vector. The Retroviridae viral vector may be, for example, a lentiviral vector. The Retroviridae viral vector may be, for example, an alpha retroviral vector or a gamma retroviral vector. In some embodiments, the Retroviridae viral vector comprises a central polypurine tract, a woodchuck hepatitis virus post-transcriptional regulatory element, a 5'-LTR, an HIV signal sequence, an HIV Psi signal 5'-splicing site, a delta-GAG element, a 3'-splicing site, and a 3'-self-inactivating LTR.

[0053] In some embodiments, the viral vector is a pseudovirus vector. The pseudovirus vector may be, for example, a pseudoadenovirus, a pseudoparvovirus, a pseudocoronavirus, a pseudorhabdovirus, a pseudoparamyxovirus, a pseudopicornavirus, a pseudoalphavirus, a pseudoherpesvirus, a pseudopoxvirus, and a pseudoretroviridae virus. In some embodiments, the pseudovirus vector is a lentiviral vector. In some embodiments, the pseudovirus vector includes one or more envelope proteins from a virus selected from the group consisting of vesicular stomatitis virus VSV, RD114 virus, MLV, FeLV, VEE, HFV, WDSV, SFV, rabies virus, ALV, BIV, BLV, EBV, CAEV, SNV, ChTLV, STLV, MPMV, SMRV, RAV, FuSV, MH2, AEV, AMV, avian sarcoma virus CT10, and EIAV. For example, in some embodiments, the pseudovirus vector includes a VSV-G envelope protein.

[0054] In some embodiments of any of the methods described herein, the method further comprises culturing the starting population of γδ T cells in the presence of exogenous IL-2 and / or IL-15.

[0055] In some embodiments, at least 10% (e.g., at least 20%, 30%, 40%, 50% 60%, 70%, 80%, 90%, 95%, 97%, or 99%) of the γδ T cell population expresses IL-15Rβ. In some embodiments, at least 50% of the γδ T cell population expresses IL-15Rβ.

[0056] In another aspect, the present invention provides a method for expanding γδT cells. The method comprises (a) providing a population of γδT cells expressing IL-15Rβ; and (b) culturing the population of γδT cells in the presence of exogenous IL-2 and / or IL-15 or variants thereof.

[0057] In some embodiments, the γδT cell population further expresses recombinant IL-15Rα or a fragment thereof. The IL-15Rα or a fragment thereof may be tethered to IL-15 or a variant thereof. In some embodiments, the C-terminus of the IL-15Rα or a fragment thereof is tethered to the N-terminus of the IL-15 or a variant thereof. In some embodiments, the N-terminus of the IL-15Rα or a fragment thereof is tethered to the C-terminus of the IL-15 or a variant thereof.

[0058] In another aspect, the present invention provides a method for expanding γδT cells. The method comprises (a) providing a population of γδT cells expressing IL-15Rβ and IL-15 or a variant thereof; and (b) culturing the γδT cells, wherein the IL-15 or a variant thereof expands the population of γδT cells.

[0059] In some embodiments, the method further comprises culturing the population of γδ T cells in the presence of exogenous IL-2.

[0060] In some embodiments, the γδT cell population further expresses recombinant IL-15Rα or a fragment thereof. The fragment of IL-15Rα may include, for example, a soluble fragment. The soluble fragment may include, for example, a sushi domain. In some embodiments, the sushi domain is attached to an Fc domain.

[0061] In some embodiments, the IL-15Rα or fragment thereof is tethered to IL-15 or a variant thereof. In some embodiments, the C-terminus of the IL-15Rα or fragment thereof is tethered to the N-terminus of the IL-15 or a variant thereof. In some embodiments, the N-terminus of the IL-15Rα or fragment thereof is tethered to the C-terminus of the IL-15 or a variant thereof. As used herein, "mbIL-15" refers to a membrane-bound IL-15Rα tethered to IL-15 (e.g., wherein the C-terminus of the IL-15Rα is tethered to the N-terminus of the IL-15). BRIEF DESCRIPTION OF THE DRAWINGS

[0062] Figure 1 A-1C is a schematic overview of conventional and novel IL-15 armored constructs. Figure 1A is a diagram showing the armoring strategies evaluated in the present invention. Conventional armoring constructs used in the context of αβT cells, NK cells, and iNKT cells utilize secreted (sIL-15) or membrane-tethered IL-15 (mbIL-15) constructs. The novel armoring strategy is based on the introduction of a common β chain (also known as IL-2Rβ, IL-15Rβ, or CD122) alone or in combination with a wild-type or IL-15-tethered IL-15Rα (CD215) chain. Figure 1 B shows the domain structure of a conventional armored CAR encoding a gammaretroviral vector. Figure 1 C shows the domain structure of the novel armored CAR encoding gammaretroviral vector.

[0063] Figure 2 A-2C are graphs evaluating the effects of conventional armoring strategies on Vδ1 T cell expansion and phenotype. Figure 2 A shows the fold expansion of CAR-modified unarmored (muCAR19) and conventionally armored (muCAR19.sIL-15 and muCAR19-mbIL-15) Vδ1 T cells. Figure 2 B shows the analysis of CAR, IL-15 and IL-15Rα surface expression in mbIL-15 armored CAR-modified Vδ1 T cells by flow cytometry. Figure 2 C shows the analysis of IL-15 production by ELISA in unarmored (muCAR19) and secretory IL-15 armored (muCAR19.sIL-15) CAR-modified Vδ1 T cells.

[0064] Figure 3 A-3C are graphs evaluating the effects of conventional armoring strategies on the cytotoxicity, survival, and proliferation induced by repeated antigen stimulation of Vδ1 T cells. Figure 3 A shows a comparison of the cytotoxic activity of unarmored (muCAR19) and conventionally armored Vδ1 T cells against the NALM-6 acute lymphoblastic leukemia cell line. Figure 3 B shows the analysis of the survival of unarmored and conventionally armored CAR-modified Vδ1 T cells by flow cytometry. Figure 3 C shows the fold expansion of CAR-modified unarmored and conventionally armored Vδ1 T cells during three rounds of repeated antigen stimulation with CD19+NALM-6 cells.

[0065] Figure 4 Figure 1 is a graph evaluating the effect of mbIL-15 armor on the fold expansion of CAR-modified Vδ1 T cells. The graph shows a comparison of the fold expansion of unarmored and mbIL-15 armored Vδ1 CAR-T cells in the presence of high and low IL-15 concentrations.

[0066] Figure 5 Figure 2 shows the expression of IL-15 receptor chain components analyzed using LEGENDScreen. Heat map showing the expression of IL-15Rα (CD215), IL-15Rβ (CD122, also known as IL-2Rβ), and the common γ chain (CD123, γ c )'s percentage of Vδ1T cells.

[0067] Figure 6 A and Figure 6 B is a graph evaluating the effect of IL-15Rβ chain transfer in the presence of mbIL-15 or IL-15Rα chain. Figure 6 A shows the comparison of fold expansion of unarmored (muCAR19), mbIL-15 armored (muCAR19.α.15), mbIL-15 and IL-15β chain armored (muCAR19.α.15.β), and IL-15Rα and β armored (muCAR19.α.β) CAR-modified Vδ1 T cells. Figure 6 B shows the fold expansion of Vδ1 T cells expressing α.15, α.β or α.15.β chains in the presence of low and high IL-15 concentrations.

[0068] Figure 7 A-7C is a graph evaluating the effect of IL-15Rβ chain transfer on the cytotoxicity, survival, and proliferation induced by repeated antigen stimulation of Vδ1 T cells. Figure 7 A shows a comparison of the cytotoxic activity of conventionally armored (mbIL-15,α.15), mbIL-15 and IL-15β chain armored (muCAR19.α.15.β), and IL-15Rα and β armored (muCAR19.α.β) CAR-modified Vδ1 T cells against the NALM-6 acute lymphoblastic leukemia cell line. Figure 7 B shows in absence and presence ( Figure 7 C) Effects of armor on fold expansion, enrichment, and target (NALM-6) clearance of CAR-modified Vδ1 T cells during repeated antigen stimulation with CD19+NALM-6 cells in the presence of exogenous IL-15.

[0069] Figure 8 A and Figure 8 B is a graph showing analysis of CAR and IL-15R chain expression 3 days after transduction. Figure 8 A shows comparison of CAR expression in Vδ1 T cells armored with novel armored constructs 3 days after transduction. Figure 8 B shows the comparison of IL-15Rα, IL-15Rβ, common γ chain and tethered IL-15 expression in armored CAR-modified Vδ1 T cells.

[0070] Fig. 9 A and Fig. 9 B is a graph evaluating the effect of IL15Rβ chain transfer alone or in combination with wild-type or IL-15-tethered IL-15Rα chain on Vδ1 T cell expansion. Fig. 9 A shows the comparison of fold expansion of IL-15Rβ (muCAR19.β), mbIL-15 and IL-15Rβ (muCAR19.α.15.β), and IL-15Rα and β (muCAR19.α.β) armored CAR-modified Vδ1 T cells. Fig. 9 B shows the fold expansion of CAR-modified Vδ1 T cells armored with the novel construct.

[0071] Fig.10 A-10D is a graph showing the phenotypic analysis of the frozen-thawed, armored CAR-modified Vδ1 T cell drug product. Fig.10 A shows analysis of CAR expression in armored Vδ1 T cells. Fig.10 B shows the comparison of IL-15Rα, IL-15Rβ, common γ chain and tethered IL-15 expression in armored CAR-modified Vδ1 T cells. Fig.10 C shows a comparison of CAR expression in armored Vδ1 T cells grown in the presence of high and low IL-15 concentrations 3 days after transduction (day 7) and on the day of harvest (day 14). Fig.10 D shows flow cytometric analysis of the expression of immune cell activation and inhibition markers in CAR+ve and CAR-ve Vδ1 T cell fractions

[0072] Fig.11 A-11E is a graph showing the cytotoxic activity of freshly thawed armored CAR-modified Vδ1 T cell drug product. The cytotoxic activity of armored cells was not observed in the absence of IL-15 ( Fig.11 A) and existence ( Fig.11 B) shows the cytotoxicity of CD19-targeted CAR-engineered cells against antigen-negative targets ( Fig.11 C) The AML target MV4-11 is shown on the left, while MOLM-13 is shown on the right. Fig.11 D shows the cytotoxicity of CD123-targeted CAR-engineered cells that are unarmored (CAR123) or armored with mbIL-15 and IL-15Rβ (CAR123.α.15.β). Fig.11 E shows the cytotoxicity of mesothelin-targeting CAR-engineered cells that are unarmored (Meso-CAR) or armored with mbIL-15 and IL-15Rβ (Meso-CAR.α.15.β).

[0073] Fig.12A-12D are graphs showing in vitro survival of freshly thawed, armored CAR-modified Vδ1 T cell drug product in the absence of exogenous IL-15. Fig.12 A shows the fold expansion of armored CAR-modified Vδ1 T cells. Fig.12 B Relative fold change in the number of non-transduced (CAR-ve) Vδ1 T cells. Fig.12 C shows the enrichment of CAR-modified Vδ1 T cells. Fig.12 D shows the percentage of live lymphocytes during the assay.

[0074] Fig.13 A-13F are graphs evaluating the effects of repeated antigen exposure on armored CAR-modified Vδ1 T cell proliferation, enrichment, and target cell clearance. Fig.13 A-13C shows repeated antigen stimulation with NALM-6 cells in the presence of supraphysiological concentrations (10 ng / mL), and Fig.13 D-13F displayed physiological IL-15 concentrations (70 pg / mL).

[0075] Fig.14 A-14M is a schematic diagram and results of evaluating the in vivo performance of armored CAR-modified Vδ1 T cells in NSG and NOG-IL15 mice challenged with NALM6 tumor cells. Fig.14 A shows the in vivo study design and experimental study grouping. Fig.14 B shows in vivo efficacy in NSG mice with exogenous IL-15. Fig.14 C demonstrates in vivo efficacy in NSG mice without exogenous IL-15. Fig.14 D shows in vivo efficacy in NOG-hIL15 mice. Fig.14 E shows the in vivo persistence of CD19 CAR+ and CAR-Vδ1 T cells in the bone marrow of NSG mice on day 3 after administration. Fig.14 F The Vδ1CD19CAR+ proportion of drug product after thawing was compared with cells recovered from the bone marrow of NSG mice 3 days after dosing. Fig.14 G shows in vivo efficacy in NSG mice with exogenous IL-15 until the end of the study on day 20 / 21. Fig.14 H demonstrates in vivo efficacy in NSG mice without exogenous IL-15 until the end of the study on day 20 / 21. Fig.14 I shows in vivo efficacy in NOG-hIL15 mice until the end of the study on day 20 / 21. Fig.14 J The Vδ1CD19 CAR+ proportion of drug product after thawing was compared with cells recovered from the bone marrow of NSG mice 3 and 14 days after dosing. Fig.14K Comparison of the number of Vδ1CD19 CAR+ and CAR- cells recovered from bone marrow samples harvested from NSG mice given exogenous IL-15 on day 14 post-dose. Fig.14 LComparison of the number of Vδ1CD19 CAR+ and CAR- cells recovered from bone marrow samples harvested on day 14 after dosing from NSG mice that did not receive exogenous IL-15. Fig.14 M was compared with the number of NALM-6 tumor cells recovered from bone marrow samples harvested on day 14 after dosing from NSG mice that did not receive exogenous IL-15.

[0076] Fig.15 A-15E was to evaluate the effects of in vitro survival and repeated antigen exposure on two different Vδ1T modified with unarmored, armored with mbIL-15 and IL-15Rβ (CAR.α.15.β), or armored with IL-15Rβ (CAR.β) targeting mesothelin CAR (YP218 or P4). Fig.15 A shows the survival of unarmored and α.15.β armored CAR T cells. Fig.15 B and Fig.15 D shows tumor confluence measured by tracking GFP fluorescence over time after treatment with different Meso-CART cell products. Fig.15 C and Fig.15 E shows the fold expansion of CAR T cells during repeated antigen stimulation assay.

[0077] Fig.16 A and Fig.16 B is a schematic diagram and results of evaluating the in vivo performance of unarmored, mbIL-15 and IL-15Rβ armored, and IL-15Rβ armored MesoCAR modified Vδ1 T cells (P4 CAR, P4CAR.α.15.β, and P4 CAR.β, respectively) in the disseminated A549 tumor model. The A549 cell line was engineered to express mesothelin (A549-Meso). Fig.16 A Schematic diagram showing the model used. Fig.16 B shows the in vivo efficacy of the studied product. DETAILED DESCRIPTION

[0078] The present invention provides compositions and methods for engineering γδT cells (e.g., vδ1T cells and vδ2T cells) to respond to IL- 15. IL-15 is a cytokine and T cell growth factor that binds to and signals through a receptor complex consisting of an IL-2 receptor β subunit (IL-15Rβ), an IL-15 receptor α subunit (IL-15Rα), and a common γ chain.

[0079] Traditional chimeric antigen receptor (CAR) armor attempts to improve the persistence, growth or other properties of CAR+ cells by making the cells also express IL-15 (secreted or membrane-bound). CAR+ cells co-expressing IL-15 in the same construct or separately will reduce the responsiveness of the cells to exogenous IL-15. The present invention introduces a positive IL-15 signaling loop and enhances the responsiveness of CAR+ cells to IL-15 by co-expressing IL-15 receptor β and / or α subunits, which appears to be limited in some cells (including γδT cells). This can increase the sensitivity of CAR+ cells, even in the absence of armored constructs. The described strategy can be used alone or in combination with CAR to enhance the persistence and proliferation of γδT cells.

[0080] Traditional methods for engineering IL-15 signaling loops in NK cells and αβT cells include transduction using constructs encoding IL-15Rα. In each case, NK cells or αβT cells expressing IL-15Rα and treated with IL-15 increased cell proliferation, survival, and toxicity. In contrast, γδT cells engineered with IL-15Rα showed reduced proliferation and had a moderate effect on survival. The present invention is based on the following unexpected discovery: γδT cells can be engineered with recombinant IL-15Rβ to effectively introduce a positive IL-15 signaling loop. This is unexpected because it is expected that IL-15Rα will be necessary for IL-15 responsiveness.

[0081] The compositions and methods described herein feature γδT cells and populations thereof engineered to express recombinant IL-15Rβ. These IL-15Rβ-engineered γδT cells provide efficient proliferation and survival in the presence of IL-15 and provide substantial cytotoxicity for a variety of therapeutic approaches.

[0082] I. Definitions

[0083] It should be understood that the aspects and embodiments of the present invention described herein include "comprising aspects and embodiments," "consisting of aspects and embodiments," and "consisting essentially of aspects and embodiments." As used herein, the singular forms "a," "an," and "the" include plural referents unless otherwise indicated.

[0084] The term "about" as used herein refers to the common error range of individual values ​​that are readily known to those skilled in the art. Reference to "about" values ​​or parameters herein includes (and describes) embodiments of the values ​​or parameters themselves. In some cases, "about" encompasses changes of +20%, in some cases +10%, in some cases +5%, in some cases +1%, or in some cases +0.1% relative to the specified value, as such changes are appropriate for performing the disclosed methods.

[0085] As used herein, the term "engineered γδ T cells" refers to γδ T cells that express a transgene (ie, a gene that has been transduced into the engineered γδ T cells or their parental cells).

[0086] As used herein, the term "primed γδT cells" refers to a starting population (e.g., an endogenous γδT cell population) that is affected by culture conditions. In some cases, the sensitized γδT cells have a different functional viral entry receptor profile relative to their unprimed counterparts before undergoing culture conditions. In some embodiments, the sensitized γδT cell population is an expanded γδT cell population.

[0087] As used herein, an "expanded γδ cell population" refers to a hematopoietic cell population including γδT cells, which is cultured under conditions and durations that induce γδ cell expansion, i.e., increase the number of γδ cells. Similarly, as used herein, an "expanded Vδ1T cell population" refers to a hematopoietic cell population including Vδ1T cells, which is cultured under conditions and durations that induce Vδ1T cell expansion, i.e., increase the number of Vδ1 cells. Similarly, as used herein, an "expanded Vδ2T cell population" refers to a hematopoietic cell population including Vδ2T cells, which is cultured under conditions and durations that induce Vδ2T cell expansion, i.e., increase the number of Vδ2 cells.

[0088] As used herein, a "population" of γδT cells refers to a group of three or more γδT cells (e.g., at least 10, at least 102, at least 103, at least 104, at least 105, at least 106, at least 107, at least 108, at least 109, at least 1010, at least 1011, at least 1012, or at least 1013) γδT cells (e.g., engineered γδT cells). A population of a particular cell type (e.g., an endogenous γδT cell population, a sensitized γδT cell population, or an engineered γδT cell population) refers to that type of cell rather than a different type of cell within a broader population. For example, if 10% of the cells in a starting population of 108 T cells are γδT cells, the starting population of γδT cells is 107.

[0089] As used herein, "armored protein" refers to a protein encoded by a transgene, which, when expressed by a γδT cell (e.g., a γδT cell expressing a CAR), increases the persistence of γδT cells, increases the proliferation of γδT cells, or increases the cytotoxicity of γδT cells to target cells, such as via signal transduction (e.g., cytokine signal transduction), to improve, for example, cell persistence, cell viability, activation, and other desired properties. Armored protein may be a membrane-bound protein or a soluble protein. For example, armored proteins include membrane-bound proteins, such as membrane-bound receptors (e.g., IL-15R, such as IL-15Rβ and IL-15Rα, αβTCR, natural cytotoxicity receptors (e.g., NKp30, NKp44 or NKp46), cytokine receptors (e.g., IL-12 receptor) and / or chemokine receptors (e.g., CCR2 receptor) and / or membrane-bound ligands or cytokines (e.g., membrane-bound IL-15, membrane-bound IL-7, membrane-bound CD40L, membrane-bound 4-1BB, membrane-bound 4-1BBL, membrane-bound CCL19). Additionally or alternatively, armored proteins may be soluble proteins, such as soluble ligands or cytokines (e.g., soluble IL-15, soluble IL-7, soluble IL-12, soluble CD40L, soluble 4-1BBL and / or soluble CCL19). In some embodiments, armored proteins are not antigen-specific.

[0090] As used herein, "IL-15" refers to natural or recombinant IL-15 or a variant thereof having at least 70% (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, e.g., at least 85%) sequence identity over an equal length portion that acts as an agonist of one or more IL-15 receptor (IL-15R) subunits (e.g., mutant proteins, analogs, subunits, receptor complexes, fragments, isoforms, and peptidomimetics thereof). Like IL-2, IL-15 is a known T cell growth factor that can support the proliferation of the IL-2-dependent cell line CTLL-2. IL-15 was first reported by Grabstein et al. (Science 264.5161:965-969, 1994) as a mature protein of 114 amino acids. As used herein, the term "IL-15" means natural or recombinant IL-15 and its mutant proteins, analogs, subunits or complexes (e.g., receptor complexes, e.g., sushi peptides, as described in PCT Publication No. WO 2007 / 046006), and each of which can stimulate the proliferation of CTLL-2 cells. In a CTLL-2 proliferation assay, supernatants of cells transfected with recombinant expression precursors and in-frame fusions of mature forms of IL-15 can induce CTLL-2 cell proliferation.

[0091] Human IL-15 can be obtained according to the procedure described by Grabstein et al. (Science 264.5161:965-969, 1994) or conventional procedures such as polymerase chain reaction (PCR). Human IL-15 cDNA was deposited on February 19, 1993 at and was assigned accession number 69245.

[0092] The amino acid sequence of human IL-15 (Gene ID 3600) is found in Genbank under accession loci NP000576.1 GI: 10835153 (isoform 1) and NP_751915.1 GI: 26787986 (isoform 2). The amino acid sequence of murine (Mus musculus) IL-15 (Gene ID 16168) is found in Genbank under accession loci NP_001241676.1 GI: 363000984.

[0093] IL-15 may also refer to IL-15 derived from a variety of mammalian species, including, for example, humans, apes, cattle, pigs, horses and mice. As referred to herein, an IL-15 "mutant" is a polypeptide having an amino acid sequence that differs from a native mammalian IL-15 polypeptide due to one or more amino acid deletions, insertions and / or substitutions. A variant may comprise a conservative substitution sequence, meaning that a given amino acid residue is replaced by a residue having similar biochemical characteristics. Examples of conservative substitutions include substitutions of one aliphatic residue for another aliphatic residue, such as substitutions of Ile, Val, Leu or Ala for each other, or substitutions of one polar residue for another polar residue, such as substitutions between Lys and Arg; Glu and Asp; or Gln and Asn. Other such conservative substitutions, for example, substitutions of entire regions having similar hydrophobic characteristics, are well known. Naturally occurring IL-15 variants are also encompassed by the present invention. Examples of such variants are proteins produced by alternative mRNA splicing events or by proteolytic cleavage of IL-15 proteins, in which IL-15 binding properties are maintained. Alternative splicing of mRNA can produce truncated but biologically active IL-15 proteins. The variation attributable to protein degradation includes, for example, differences in the N or C termini after expression in different types of host cells, which is due to protein degradation to remove one or more terminal amino acids (usually 1-10 amino acids) from the IL-15 protein. In some embodiments, the end of the protein can be modified, for example, with chemical groups such as polyethylene glycol to change its physical properties (Yang et al., Cancer 76: 687-694, 1995). In some embodiments, the end or interior of the protein can be modified with additional amino acids (Clark-Lewis et al., PNAS 90: 3574-3577, 1993).

[0094] As used herein, "IL-2 receptor β subunit", "IL-2Rβ", "IL-15 receptor β subunit" and "IL-15Rβ" are used interchangeably herein to refer to native or recombinant IL-15Rβ or variants having at least 70% (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, e.g., at least 85%) sequence identity over an equal length portion that acts as a receptor for one or more of IL-2 or IL-15 (e.g., a mutein, analog, fragment, isoform and peptidomimetic thereof). IL-15Rβ includes full length and fragments thereof. IL-2Rβ (referred to herein as IL-15Rβ) is a known T cell growth factor receptor that can support the proliferation of the IL-2-dependent cell line CTLL-2. IL-2Rβ is a mature protein of 551 amino acids. As used herein, the term "IL-15Rβ" means native or recombinant IL-2Rβ and its muteins, analogs, subunits or complexes.

[0095] The amino acid sequence of human IL-2Rβ (Gene ID 3560) is found in Genbank under accession loci NP_000869, NP_001333151 and NP_001333152. The amino acid sequence of murine (Mus musculus) IL-2Rβ (Gene ID 16185) is found in Genbank under accession loci NP_032394.

[0096] IL-15Rβ may also refer to IL-15Rβ derived from a variety of mammalian species, including, for example, humans, apes, cows, pigs, horses, and mice. As referred to herein, an IL-15Rβ "mutant" is a polypeptide having an amino acid sequence that differs from a native mammalian IL-15Rβ polypeptide due to one or more amino acid deletions, insertions, and / or substitutions. A variant may comprise a conservative substitution sequence, meaning that a given amino acid residue is replaced by a residue having similar biochemical characteristics. Examples of conservative substitutions include substitutions of one aliphatic residue for another aliphatic residue, such as substitutions of Ile, Val, Leu, or Ala for each other, or substitutions of one polar residue for another polar residue, such as substitutions between Lys and Arg; Glu and Asp; or Gln and Asn. Other such conservative substitutions, for example, substitutions of entire regions having similar hydrophobic characteristics, are well known. Naturally occurring IL-15Rβ variants are also encompassed by the present invention. Examples of such variants are proteins produced by alternative mRNA splicing events or proteolytic cleavage of the IL-15Rβ protein, in which the IL-15Rβ binding properties are retained. Alternative splicing of mRNA can produce truncated but biologically active IL-15Rβ proteins. Variations attributable to proteolysis include, for example, differences in the N or C termini after expression in different types of host cells due to proteolytic removal of one or more terminal amino acids (usually 1-10 amino acids) from the IL-15Rβ protein.

[0097] As used herein, "IL-15 receptor alpha subunit" and "IL-15Rα" refer to natural or recombinant IL-15Rα or a variant thereof that acts as an IL-15 receptor (e.g., a mutant protein, analog, fragment, isoform, and peptidomimetic thereof). IL-15Rα includes full length and fragments thereof. IL-15Rα is a known T cell growth factor receptor. IL-15Rα is a mature protein of 267 amino acids. As used herein, the term "IL-15Rα" means natural or recombinant IL-15Rα and a mutant protein, analog, subunit, or complex thereof. Fragments of IL-15Rα include soluble fragments, such as sushi peptides, as described in PCT Publication No. WO 2007 / 046006. Soluble fragments (e.g., sushi peptides, e.g., fragments containing residues 31-95 of IL-15Rα or a variant thereof, which have at least 70% (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, e.g., at least 85%) sequence identity over an equal length portion) also include mutant proteins, analogs, fragments, isoforms, and peptidomimetics thereof. In some embodiments, the soluble fragment is attached to an Fc domain, e.g., Fc-sushi or sushi-Fc.

[0098] The amino acid sequence of human IL-15Rα (Gene ID 3601) is found in Genbank under accession loci NP_001230468, NP_001243694, NP_002180, NP_751950 and NP_001338024. The amino acid sequence of murine (Mus musculus) IL-15Rα (Gene ID 16169) is found in Genbank under accession loci NP_001258426.

[0099] IL-15Rα may also refer to IL-15Rα derived from a variety of mammalian species, including, for example, humans, apes, cattle, pigs, horses, and mice. As referred to herein, an IL-15Rα "mutant" is a polypeptide having an amino acid sequence that differs from a native mammalian IL-15Rα polypeptide due to one or more amino acid deletions, insertions, and / or substitutions. The variant may comprise a conservative substitution sequence, meaning that a given amino acid residue is replaced by a residue having similar biochemical characteristics. Examples of conservative substitutions include substitutions of one aliphatic residue for another aliphatic residue, such as substitutions of Ile, Val, Leu, or Ala for each other, or substitutions of one polar residue for another polar residue, such as substitutions between Lys and Arg; Glu and Asp; or Gln and Asn. Other such conservative substitutions, for example, substitutions of entire regions having similar hydrophobic characteristics, are well known. Naturally occurring IL-15Rα variants are also encompassed by the present invention. Examples of such variants are proteins produced by alternative mRNA splicing events or proteolytic cleavage of IL-15Rα proteins, in which IL-15Rα binding properties are maintained. Alternative splicing of mRNA can produce truncated but biologically active IL-15Rα proteins. Variations attributable to proteolysis include, for example, differences in the N or C termini after expression in different types of host cells, which are due to proteolysis removing one or more terminal amino acids (usually 1-10 amino acids) from the IL-15Rα protein. In some embodiments, the ends of the protein may be modified, for example, with chemical groups such as polyethylene glycol to change its physical properties (Yang et al., Cancer 76: 687-694, 1995). In some embodiments, the ends or interiors of the protein may be modified with additional amino acids (Clark-Lewis et al., PNAS 90: 3574-3577, 1993).

[0100] As used herein, "internal ribosome entry site" or "IRES" refers to an RNA element that allows translation to be initiated in a 5' cap-independent manner. In some embodiments, polyribonucleotides as described herein include one or more internal ribosome entry site (IRES) elements. In some embodiments, the IRES is operably connected to one or more transgenic sequences (e.g., each IRES is operably connected to one or more expressed sequences). In embodiments, the IRES is located between the 5' end of a heterologous promoter and a coding sequence. IRES may include an RNA sequence that can engage a eukaryotic ribosome. In some embodiments, the IRES element is at least about 5nt, at least about 8nt, at least about 9nt, at least about 10nt, at least about 15nt, at least about 20nt, at least about 25nt, at least about 30nt, at least about 40nt, at least about 50nt, at least about 100nt, at least about 200nt, at least about 250nt, at least about 350nt or at least about 500nt.

[0101] As used herein, the phrase "in an amount effective to" refers to an amount that induces a detectable result (eg, a statistically significant increased number of cells relative to their starting population, eg, p<0.05).

[0102] As used herein, an "expanded γδ cell population" refers to a hematopoietic cell population including γδT cells, which is cultured under conditions and for a duration that induces γδ cell expansion, i.e., increases the number of γδ cells. Similarly, as used herein, an "expanded Vδ1T cell population" refers to a hematopoietic cell population including Vδ1T cells, which is cultured under conditions and for a duration that induces Vδ1T cell expansion, i.e., increases the number of Vδ1 cells. Similarly, as used herein, an "expanded Vδ2T cell population" refers to a hematopoietic cell population including Vδ2T cells, which is cultured under conditions and for a duration that induces Vδ2T cell expansion, i.e., increases the number of Vδ2 cells.

[0103] The term "marker" herein refers to a DNA, RNA, protein, carbohydrate, glycolipid, or cell-based molecular marker, the expression or presence of which in a patient's sample can be detected by standard methods (or methods disclosed herein).

[0104] The cell or cell colony of the marker of "expression" concern is a cell or cell colony in which the mRNA encoding the protein or the protein itself (including its fragment) is determined to be present in the cell or colony. The expression of the marker can be detected by various means. For example, in some embodiments, the expression of the marker refers to the surface density of the marker on the cell. For example, the mean fluorescence intensity (MFI) used as the readout of flow cytometry represents the density of the marker on the cell colony. It should be understood by those skilled in the art that the MFI value depends on the staining parameters (e.g., concentration, duration and temperature) and the fluorescent dye composition. However, when considered in the case of appropriate controls, the MFI can be quantitative. For example, if the MFI of the antibody of the marker is significantly higher than the MFI of the appropriate isotype control antibody on the same cell colony when dyed under comparable conditions, it can be considered that the cell colony expresses the marker. In addition or alternatively, according to conventional flow cytometry analysis methods (e.g., by setting the gate according to isotype or "fluorescence minus one" (FMO) control), using positive and negative gates, the cell colony can be referred to as expressing the marker on a cell-by-cell basis. By this measure, a population can be said to "express" a marker if the number of cells detected that are positive for the marker is significantly above background (eg, by gating on an isotype control).

[0105] As used herein, "functional expression of the VSV-G entry receptor" refers to a VSV-G entry receptor expression level sufficient to mediate detectable VSV-G entry in at least 5% of the target cell population, as measured by a β-lactamase-Vpr (BlaM-VpR)-based assay. See, e.g., Cavrois et al., Nat Biotechnol. 11: 1151-1154, 2002. Conversely, in a cell population that "lacks functional expression of the VSV-G entry receptor," greater than 95% of the cell population lacks a VSV-G entry receptor expression level sufficient to mediate detectable VSV-G entry, as measured by a BlaM-VpR-based assay.

[0106] As used herein, when the expression of a colony is represented by the percentage of positive cells and the percentage is compared with the corresponding percentage of the positive cells of a reference colony, the percentage difference is the percentage of the parent colony of each corresponding colony. For example, if a marker is expressed on 10% of the cells of colony A and the same marker is expressed on 1% of the cells of colony B, the marker positive cell frequency of colony A is said to be 9% greater than colony B (i.e., 10%-1%, rather than 10% ÷ 1%). When the frequency is multiplied by the number of cells in the parent colony, the difference in the absolute number of cells is calculated. In the example given above, if there are 100 cells in colony A and 10 cells in colony B, relative to colony B, colony A has 100 times of cell numbers, i.e., (10% x 100) ÷ (1% x 10).

[0107] The expression level of a marker can be a nucleic acid expression level (e.g., a DNA expression level or an RNA expression level, e.g., an mRNA expression level). Any suitable method for determining nucleic acid expression levels can be used. In some embodiments, nucleic acid expression levels are measured using qPCR, rtPCR, RNA-seq, multiplex qPCR or RT-qPCR, microarray analysis, serial analysis of gene expression (SAGE), techniques, in situ hybridization (e.g., FISH), or a combination thereof.

[0108] As used herein, the "reference population" of a cell refers to a cell population corresponding to the cell of interest, and the phenotype of the cell of interest is measured relative to the population. For example, the expression level of a marker on a separate population of γδ cells derived from non-hematopoietic tissue can be compared with the expression level of the same marker on γδT cells derived from hematopoietic tissue (e.g., blood-resident γδ cells, e.g., blood-resident γδ cells derived from the same donor or different donors) or on γδT cells derived from non-hematopoietic tissues amplified under different conditions (e.g., in the presence of substantial TCR activation, in the presence of exogenous TCR activators (e.g., anti-CD3), or in substantial contact with stromal cells (e.g., fibroblasts). The population can also be compared with itself in an earlier state. For example, a reference population can be a separate cell population before its amplification. In this case, the amplified population is compared with its own composition before the amplification step, that is, in this case, its past composition is a reference population.

[0109] As used herein, the term "chimeric antigen receptor" or alternatively "CAR" refers to a recombinant polypeptide construct including an extracellular antigen binding domain, a transmembrane domain, and an intracellular domain that optionally propagates activation signals and / or co-stimulatory signals for activating cells. In some embodiments, the CAR includes an optional leader sequence at the N-terminus of a CAR fusion protein. In some embodiments, the CAR lacks an intracellular (e.g., signaling) domain.

[0110] As used herein, the term "tether" or "tethered" refers to a polypeptide that, when present, connects two or more polypeptides (e.g., IL-15Rα or a fragment thereof (e.g., a sushi domain) and IL-15 or a variant thereof). In general, the tether can be about, for example, 1 to 100 (e.g., 5 to 50, 5 to 30, 5 to 20, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 100) amino acids in length. In some embodiments, the tether is highly flexible and can be rich in glycine (G) and / or serine (S) residues, which can be present in the form of GS repeats. In some embodiments, the tether can connect the C-terminus of the first protein to the N-terminus of the second protein. In other embodiments, the tether can connect the C-terminus of the second protein to the N-terminus of the first protein.

[0111] As used herein, the term "percent identity (%)" refers to the percentage of amino acid residues of a candidate sequence (e.g., an IL-15Rβ variant) that are identical to amino acid residues of a reference sequence (e.g., a wild-type IL-15Rβ polypeptide) after aligning the sequences and introducing gaps (if necessary) to achieve the maximum percent identity (i.e., gaps may be introduced in one or both of the candidate and reference sequences to achieve optimal alignment, and non-homologous sequences may be ignored for comparison purposes). Alignment for the purpose of determining percent identity may be achieved in various ways within the skill in the art, for example, using publicly available computer software such as BLAST, ALIGN, or Megalign (DNASTAR) software. One skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms necessary to achieve maximal alignment over the full length of the sequences being compared. In some embodiments, the percent amino acid sequence identity of a given candidate sequence to, with, or against a given reference sequence (which may alternatively be expressed as a given candidate sequence having or including a certain percent amino acid sequence identity to, with, or against a given reference sequence) is calculated as follows:

[0112] 100x(A / B ratio)

[0113] Where A is the number of amino acid residues scored as identical in an alignment of the candidate sequence with the reference sequence, and Where B is the total number of amino acid residues in the reference sequence. In some embodiments where the length of the candidate sequence is not equal to the length of the reference sequence, the percent amino acid sequence identity between the candidate sequence and the reference sequence will not be equal to the percent amino acid sequence identity between the reference sequence and the candidate sequence.

[0114] As used herein, "2A peptide" refers to a class of 18-22 amino acid long peptides that share the core sequence motif of DxExNPGP, where X is any amino acid. The 2A peptide may be a foot-and-mouth disease virus 182A (F2A) peptide, an equine rhinitis A virus 2A (E2A) peptide, a porcine teschovirus-12A (P2A) peptide, or a schizontopharynx virus 2A (T2A) peptide.

[0115] "Immune response" is as understood in the art, and generally refers to a biological response in a vertebrate body to foreign substances or abnormal substances (such as cancer cells), which protects the organism from damage to these substances and diseases caused by them. The immune response is mediated by the action of one or more cells of the immune system (for example, T lymphocytes, B lymphocytes, natural killer (NK) cells, macrophages, eosinophils, mast cells, dendritic cells or neutrophils) and soluble macromolecules (including antibodies, cytokines and complement) produced by any of these cells or the liver, resulting in selective targeting, binding, damage, destruction and / or elimination of invading pathogens, cells or tissues infected by pathogens, cancer cells or other abnormal cells in the vertebrate body, or in the case of autoimmunity or pathological inflammation, normal human cells or tissues. Immune response includes, for example, activation or suppression of T cells, such as effector T cells, Th cells, CD4+ cells, CD8+T cells or Treg cells, or activation or suppression of any other cells of the immune system, such as NK cells.

[0116] "Immunotherapy" refers to the treatment of a subject suffering from a disease or at risk of contracting a disease or suffering recurrence of a disease by methods that include inducing, enhancing, suppressing or otherwise altering the immune system or immune response.

[0117] As used herein, the terms "treat," "treatment," or "treatment of" when used in the context of treating a disease or disorder (e.g., cancer) in a subject refers to reducing disease pathology, reducing or eliminating disease symptoms, promoting improved survival, and / or reducing discomfort. For example, treatment may refer to the ability of a therapy to reduce one or more symptoms, signs, or causes of a disease when administered to a subject. Treatment also refers to alleviating or reducing one or more clinical symptoms and / or inhibiting or delaying the progression of a disorder and / or preventing or delaying the onset of a disease or condition.

[0118] As used herein, "cancer" refers to a broad group of diseases characterized by the uncontrolled growth of abnormal cells in the body. Unregulated cell division can lead to the formation of malignant tumors or cells that invade adjacent tissues and can metastasize to distant parts of the body via the lymphatic system or bloodstream.

[0119] As used herein, the term "effective amount" or "therapeutically effective amount" of the administered therapeutic substance (e.g., immune cells comprising polynucleotides encoding CAR) is an amount sufficient to achieve a specific prescribed or intended purpose (e.g., treating or treating cancer). An "effective amount" can be empirically determined in a conventional manner relative to a prescribed purpose.

[0120] As used herein, the term "subject", "individual" or "patient" refers to any subject, particularly a mammalian subject, for whom diagnosis, prognosis or treatment is desired. Mammalian subjects include, for example, humans, non-human primates, dogs, cats, guinea pigs, rabbits, rats, mice, horses, cows, bears, and the like.

[0121] As used herein, the terms "ug" and "uM" are used interchangeably with "μg" and "μM", respectively.

[0122] Various aspects described herein are described in further detail in the following subsections.

[0123] II. Engineering γδ T cells

[0124] II.A. γδ T cells expressing IL-15Rβ

[0125] The present invention provides engineered γδT cells expressing recombinant IL-15Rβ. Such engineered cells provide enhanced responsiveness to IL-15, even without further expression of additional IL15 receptor complex components. In some embodiments, the γδT cells lack endogenous genes encoding IL-15. Such engineered cells exhibit enhanced sensitivity to exogenous IL-15 for signal transduction.

[0126] In another embodiment, a γδ T cell expressing recombinant IL-15Rβ and recombinant IL-15 or a variant thereof is described herein. In some embodiments, the recombinant IL-15 is secreted IL-15 or a variant thereof or tethered IL-15 or a variant thereof. Such engineered cells exhibit continuous IL-15 signaling and are independent of exogenous IL-15 for signaling.

[0127] In some embodiments, the γδ T cells expressing recombinant IL-15Rβ further express recombinant IL-15Rα or a fragment thereof (e.g., a soluble fragment, such as a sushi domain). The IL-15Rα or a fragment thereof may be tethered to IL-15 or a variant thereof. In some embodiments, the C-terminus of the IL-15Rα or a fragment thereof is tethered to the N-terminus of the IL-15 or a variant thereof. In some embodiments, the N-terminus of the IL-15Rα or a fragment thereof is tethered to the C-terminus of the IL-15 or a variant thereof. Such engineered cells further respond as described herein.

[0128] The various expressed transgenes described herein can be expressed in tandem, e.g., in a single construct. For example, in some embodiments, IL-15Rβ and IL-15Rα or fragments thereof are expressed in tandem. In some embodiments, IL-15Rβ and IL-15 or variants thereof are expressed in tandem. In some embodiments, IL-15Rβ and IL-15Rα or fragments thereof are expressed in tandem. In some embodiments, IL-15Rβ, IL-15 or variants thereof, and recombinant IL-15Rα or fragments thereof are expressed in tandem.

[0129] One or more transgenes may include a linker therebetween. IL-15Rβ and IL-15Rα or a fragment thereof may include a linker therebetween. The linker may include a cleavable peptide. The cleavable peptide may be, for example, a self-cleaving peptide, such as a 2A peptide. In some embodiments, the 2A peptide is a foot-and-mouth disease virus 182A (F2A) peptide, an equine rhinitis A virus 2A (E2A) peptide, a porcine Teschovirus-12A (P2A) peptide, or a 2A (T2A) peptide of the scaly moth virus. IL-15Rβ and IL-15 or a variant thereof may include a linker therebetween. The linker may include a cleavable peptide. The cleavable peptide may be, for example, a self-cleaving peptide, such as a 2A peptide. In some embodiments, the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide, or a T2A peptide. The 2A peptide is used to connect two or more transgenes and allow the translated polypeptide to self-cleave into separate polypeptide chains (e.g., IL-15Rβ and IL-15Rα). Thus, in some embodiments, the transgene encodes a 2A peptide between the first transgene and the second transgene, optionally with a flexible linker (e.g., a GSG linker) flanking the 2A peptide. The transgene may also include one or more engineered cleavage sequences, such as a furin cleavage sequence, to remove 2A peptide residues attached to the peptide. Exemplary 2A peptides are described, for example, in Chng et al., MAbs 7:403-412, 2015 and Lin et al., Front. Plant Sci. 9:1379, 2018, the disclosures of which are hereby incorporated by reference in their entirety.

[0130] In some embodiments, IL-15Rα or a fragment thereof is tethered to IL-15 or a variant thereof. The tether may be a peptide linker of any suitable length, for example, having 1 to 100 (e.g., 5 to 50, 5 to 30, 5 to 20, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90 or 100) amino acid residues. The linker may be a flexible linker, for example, containing one or more glycine or serine.

[0131] Examples of armorins are shown in Table 1.

[0132] Table 1: Armored proteins

[0133]

[0134]

[0135]

[0136] In some aspects, the IL-15Rα polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 3. In some aspects, the IL-15Rα polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 3. In some aspects, the IL-15Rα polypeptide comprises a signal peptide sequence.

[0137] In some aspects, the IL-15 polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 2. In some aspects, the IL-15 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 2. In some aspects, the IL-15 polypeptide comprises a signal peptide sequence.

[0138] In some aspects, the IL-15Rα polypeptide is tethered to the IL-15 polypeptide via a linker. For example, wherein the IL-15Rα polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 3. In some aspects, the IL-15Rα polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3, and wherein the IL-15 polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 2. In some aspects, the IL-15 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 2. In some aspects, the linker comprises one or more peptide bonds. In some aspects, the linker comprises a peptide linker. In some aspects, the peptide linker is a flexible linker. In some aspects, the linker is a rigid linker. In some aspects, the linker is a cleavable linker. In some aspects, the linker is a Gly-Ser linker. In some aspects, the linker comprises one or more repeats of the sequence GGGS, GGGS (SEQ ID NO: 6) or a combination thereof. In some aspects, the IL-15Rα polypeptide is tethered to the IL-15 polypeptide via a linker comprising the amino acid sequence shown in SEQ ID NO: 7. In some aspects, the IL-15Rα polypeptide is tethered to the IL-15 polypeptide via a linker comprising the amino acid sequence shown in SEQ ID NO: 8. In some aspects, the IL-15Rα polypeptide is tethered to the IL-15 polypeptide via a linker comprising the amino acid sequence shown in SEQ ID NO: 9. In some aspects, the IL-15Rα polypeptide is tethered to the IL-15 polypeptide via a linker comprising the amino acid sequence shown in SEQ ID NO: 10. In some aspects, the IL-15Rα polypeptide is tethered to the IL-15 polypeptide via a linker comprising the amino acid sequence shown in SEQ ID NO: 11. In some aspects, the IL-15Rα polypeptide is tethered to the IL-15 polypeptide via a linker comprising the amino acid sequence set forth in SEQ ID NO: 12. In some aspects, the IL-15Rα polypeptide is tethered to the IL-15 polypeptide via a linker comprising the amino acid sequence set forth in SEQ ID NO:13.

[0139] In some aspects, the construct comprising an IL-15Rα polypeptide tethered to an IL-15 polypeptide is arranged in the following order from N-terminus to C-terminus: (i) N-terminus, (ii) IL-15 polypeptide, (iii) a peptide linker disclosed herein (e.g., a polypeptide comprising GGGS, GGGS (SEQ ID NO: 6) or a combination thereof); (iv) IL-15Rα polypeptide; (v) C-terminus. In some aspects, the construct comprising an IL-15Rα polypeptide tethered to an IL-15 polypeptide is arranged in the following order from N-terminus to C-terminus: (i) N-terminus, (ii) IL-15 polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2, (iii) a peptide linker disclosed herein (e.g., a polypeptide comprising GGGS, GGGS (SEQ ID NO: 6) or a combination thereof); (iv) IL-15Rα polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 3; (v) C-terminus.

[0140] In some aspects, armorin is expressed as a single polypeptide. In some aspects, armorin is expressed as a single polypeptide comprising (i) an IL-2Rβ polypeptide; (ii) a linker; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide. In some aspects, armorin is expressed as a single polypeptide comprising (i) an IL-2Rβ polypeptide; (ii) a cleavable linker; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide. In some aspects, the cleavable linker comprises a P2A sequence. In some aspects, the linker comprises an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4. In some aspects, armorin is expressed as a single polypeptide comprising (i) an IL-2Rβ polypeptide; (ii) a linker comprising the amino acid sequence set forth in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide.

[0141] In some aspects, armorin is expressed as a single polypeptide comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1; (ii) a linker comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 4. NO:3 has an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity; and wherein the IL-15 polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity with the amino acid sequence shown in SEQ ID NO:2.

[0142] In some aspects, armorin is expressed as a single polypeptide comprising (i) an IL-2Rβ polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1; (ii) a linker comprising the amino acid sequence set forth in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises the amino acid sequence set forth in SEQ ID NO:3; and wherein the IL-15 polypeptide comprises the amino acid sequence set forth in SEQ ID NO:2.

[0143] II.B. γδ T cells

[0144] γδT cells represent a subset of T cells that express a unique, defining γδT cell receptor (TCR) on their surface. This TCR consists of a gamma (γ) and a delta (δ) chain. Human γδT cells can be broadly classified into one or two types: peripheral blood-resident γδT cells and non-hematopoietic tissue-resident γδT cells. Most blood-resident γδT cells express Vδ2TCR, while this phenomenon is less common in tissue-resident γδT cells, which more frequently use Vδ1 and / or other Vδ chains. The present invention provides γδT cells transduced with a viral vector encoding a desired transgene as described herein.

[0145] In some embodiments, suitable γδT cells used as a source of engineered γδT cells described herein include Vδ1 cells, Vδ2 cells, Vδ3 cells, Vδ5 cells, and Vδ8 cells. In some embodiments, the engineered γδT cell population is derived from a Vδ1 cell or a Vδ2 cell population. In some cases, the engineered γδT cell population is derived from a non-Vδ1 / Vδ2T cell population. In some cases, the engineered γδT cell population is derived from a mixed Vδ1 cell and Vδ2 cell population.

[0146] The γδT cells described herein (e.g., endogenous γδT cells or sensitized γδT cells) may lack a vesicular stomatitis virus G glycoprotein (VSV-G) entry receptor (e.g., LDL). The γδT cells (e.g., endogenous γδT cells or sensitized γδT cells) may express ASCT-1 and / or ASCT-2. The expression of ASCT-1 and / or ASCT-2 may allow transduction with a beta retrovirus pseudotype vector (e.g., BaEV and RD114). The lack of expression of VSV-G may prevent transduction with a VSV-G pseudotype vector.

[0147] In one aspect, the present invention provides a population of γδT cells engineered to express one or more transgenes, wherein the transgenes may encode membrane-bound proteins (e.g., cell surface receptors such as chimeric antigen receptors (CARs), αβTCRs, natural cytotoxicity receptors (e.g., NKp30, NKp44, or NKp46), cytokine receptors (e.g., IL-12 receptors), chemokine receptors (e.g., CCR2 receptors), and / or membrane-bound ligands or cytokines (e.g., membrane-bound IL-15, membrane-bound IL-7, membrane-bound CD40L, membrane-bound 4-1BB, membrane-bound 4-1BB L, membrane-bound CCL19), soluble proteins (e.g., soluble ligands or cytokines, e.g., soluble IL-15, soluble IL-7, soluble IL-12, soluble CD40L, soluble 4-1BBL and / or soluble CCL19), selectable markers (e.g., reporter genes) or suicide genes. In some cases, the present invention provides a population of γδT cells engineered to express IL-15Rβ, CAR, and one or more additional transgenic encoded proteins (e.g., armored proteins). In some embodiments, one or more transgenes are codon optimized.

[0148] In some embodiments, γδT cells are transduced with a viral vector encoding a transgene (e.g., IL-15Rβ and / or CAR). In some embodiments, the viral vector is a retroviral vector. In some embodiments, the viral vector is a lentiviral vector. In some such embodiments, the cell can stably express the transgene. In some embodiments, the cell can transiently express the transgene.

[0149] In one aspect, the invention provides a cell population (e.g., an isolated cell population) of engineered γδ T cells (e.g., at least 10, 102, 103, 104, 105, 106, 107, 108, 109, 1010, 1011, 1012, or 1013 cells), wherein at least 3% (e.g., at least 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 100%, 1 In some embodiments, the invention relates to a cell population in which % (%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 99% or substantially all) of the cell population are engineered γδ T cells expressing a transgene (e.g., IL-15Rβ and / or CAR and / or one or more additional proteins).

[0150] II.C. Chimeric Antigen Receptor

[0151] Some aspects of the present disclosure relate to a γδT cell population (e.g., a Vd1+γδ cell population derived from blood or skin) comprising a γδT cell containing a heterologous nucleic acid encoding a CAR, wherein the CAR comprises an antigen binding domain that specifically binds to human mesothelin. In some aspects, the CAR comprises an antigen binding domain that specifically binds to human mesothelin (e.g., wherein the antigen binding domain comprises a sequence of any one of SEQ ID NO: 1–8). In some aspects, the cell may also include 4-1BB and CD3ζ domains. In yet another aspect, the cell relates to a γδT cell population (e.g., a Vd1+γδ cell population derived from blood or skin), which comprises a γδT cell containing a heterologous nucleic acid encoding a CAR, wherein the CAR comprises an antigen binding domain that specifically binds to human mesothelin (e.g., wherein the antigen binding domain comprises a sequence of any one of SEQ ID NO: 1–8), wherein the γδT cell also comprises a CD8 transmembrane domain. In still another aspect, the cell relates to a γδT cell population (e.g., a Vd1+γδ cell population derived from blood or skin), which comprises γδT cells containing a heterologous nucleic acid encoding a CAR, wherein the CAR comprises an antigen binding domain that specifically binds to human mesothelin (e.g., wherein the antigen binding domain comprises the sequence of any one of SEQ ID NOs: 1–8), wherein the γδT cells also comprise (a) IL-15R-β or (b) (i) IL-15R-α tethered to IL-15 or a variant thereof and (ii) IL-15R-β. In another aspect, the γδT cells described herein comprise a heterologous nucleic acid encoding a CAR, wherein the CAR comprises an antigen binding domain that specifically binds to human mesothelin (e.g., wherein the antigen binding domain comprises a sequence of any one of SEQ ID NOs: 1–8), and the γδT cells may further comprise 4-1BB and a CD3ζ domain and / or a CD8 domain and (a) IL-15R-β or (b) (i) IL-15R-α tethered to IL-15 or a variant thereof and (ii) IL-15R-β.

[0152] In some aspects, the antigen binding domain that specifically binds to human mesothelin comprises a variable heavy chain (VH) complementary determining region-1 (CDR1), VH-CDR2, VH-CDR3, a variable light chain (VL) CDR-1, VL-CDR2 and VL-CDR3. In some aspects, the VH-CDR3 comprises the amino acid sequence shown in SEQ ID NO: 16. In some aspects, the VH-CDR2 comprises the amino acid sequence shown in SEQ ID NO: 15. In some aspects, the VH-CDR1 comprises the amino acid sequence shown in SEQ ID NO: 14. In some aspects, the VL-CDR1 comprises the amino acid sequence shown in SEQ ID NO: 17. In some aspects, the VL-CDR2 comprises the amino acid sequence shown in SEQ ID NO: 18. In some aspects, the VL-CDR3 comprises the amino acid sequence shown in SEQ ID NO: 19.

[0153] In some aspects, the γδ T cells (e.g., a population of Vd1+γδ cells derived from blood or skin) comprise a heterologous nucleic acid molecule encoding a CAR, wherein the CAR comprises an antigen binding domain that specifically binds to human mesothelin, and wherein the CAR comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 14; a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 15; a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 16; a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 17; a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 18; and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 19.

[0154] In some aspects, the γδ T cells (e.g., a population of Vd1+γδ cells derived from blood or skin) comprise a heterologous nucleic acid molecule encoding a CAR, wherein the CAR comprises an antigen binding domain that specifically binds to human mesothelin, and wherein the CAR comprises: (i) a VH comprising an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 20, (ii) a VL comprising an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 21, or (iii) both of (i) and (ii).

[0155] In some aspects, the γδ T cells (e.g., a Vd1+γδ cell population derived from blood or skin) comprise a heterologous nucleic acid molecule encoding a CAR, wherein the CAR comprises an antigen binding domain that specifically binds to human mesothelin, and wherein the CAR comprises (i) a VH comprising the amino acid sequence shown in SEQ ID NO: 20, (ii) a VL comprising the amino acid sequence shown in SEQ ID NO: 21, or (iii) both (i) and (ii).

[0156] In some aspects, the antigen binding domain that specifically binds human mesothelin comprises a P4 antigen binding domain (Table 2).

[0157] In some aspects, the antigen binding domain that specifically binds to human mesothelin comprises a variable heavy chain (VH) complementary determining region-1 (CDR1), VH-CDR2, VH-CDR3, a variable light chain (VL) CDR-1, VL-CDR2 and VL-CDR3. In some aspects, the VH-CDR3 comprises the amino acid sequence shown in SEQ ID NO: 24. In some aspects, the VH-CDR2 comprises the amino acid sequence shown in SEQ ID NO: 23. In some aspects, the VH-CDR1 comprises the amino acid sequence shown in SEQ ID NO: 22. In some aspects, the VL-CDR1 comprises the amino acid sequence shown in SEQ ID NO: 25. In some aspects, the VL-CDR2 comprises the amino acid sequence shown in SEQ ID NO: 26. In some aspects, the VL-CDR3 comprises the amino acid sequence shown in SEQ ID NO: 27.

[0158] In some aspects, the γδ T cells (e.g., a population of Vd1+γδ cells derived from blood or skin) comprise a heterologous nucleic acid molecule encoding a CAR, wherein the CAR comprises an antigen binding domain that specifically binds to human mesothelin, and wherein the CAR comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 22; a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 23; a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 24; a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 25; a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 26; and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 27.

[0159] In some aspects, the γδ T cells (e.g., a population of Vd1+γδ cells derived from blood or skin) comprise a heterologous nucleic acid molecule encoding a CAR, wherein the CAR comprises an antigen binding domain that specifically binds to human mesothelin, and wherein the CAR comprises: (i) a VH comprising an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 28, (ii) a VL comprising an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 29, or (iii) both of (i) and (ii).

[0160] In some aspects, the γδ T cells (e.g., a Vd1+γδ cell population derived from blood or skin) comprise a heterologous nucleic acid molecule encoding a CAR, wherein the CAR comprises an antigen binding domain that specifically binds to human mesothelin, and wherein the CAR comprises (i) a VH comprising the amino acid sequence shown in SEQ ID NO: 28, (ii) a VL comprising the amino acid sequence shown in SEQ ID NO: 29, or (iii) both (i) and (ii).

[0161] Table 2: P4 antigen binding domain amino acid sequence

[0162]

[0163]

[0164] In some aspects, CAR also includes a hinge region between an antigen binding domain and a transmembrane domain. In some aspects, hinges are derived from immunoglobulins (e.g., from hinge regions or loop regions). In certain aspects, these hinges include, for example, IgA1, IgA2, IgG1, IgG2, IgG3, IgG4, IgD, IgE or IgM hinge regions, fragments thereof (alone or by other sequences such as CH1 or CH2 region sequences capped), or from IgA1, IgA2, IgG1, IgG2, IgG3, IgG4, IgD, IgE or IgM hinge regions. Combinations of fragments. In some aspects, the hinge comprises, for example, an IgA1, IgA2, IgG1, IgG2, IgG3, IgG4, IgD, IgE, or IgM constant domain loop region, a fragment thereof (alone or capped by, for example, additional sequences from an adjacent β-strand), or a combination of fragments from an IgA1, IgA2, IgG1, IgG2, IgG3, IgG4, IgD, IgE, or IgM loop region. In some aspects, the hinge of the present disclosure comprises a hinge region derived sequence, a loop region derived sequence, or a combination thereof.

[0165] In some aspects, the hinge region is selected from a CD8 hinge, a CD28 hinge, and an immunoglobulin hinge. In some aspects, the hinge includes a CD28 hinge. In some aspects, CAR comprises a hinge comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% sequence identity with the amino acid sequence shown in SEQ ID NO:30 (Table 3). In some aspects, CAR comprises a hinge comprising an amino acid sequence shown in SEQ ID NO:30.

[0166] Table 3: CAR sequences

[0167]

[0168] Therefore, in some aspects, the present disclosure provides a CAR (or a polynucleotide encoding a CAR), wherein the CAR comprises (i) an antigen binding domain that specifically binds to mesothelin (e.g., an anti-mesothelin scFv), (ii) a hinge region comprising the hinge region of CD28, (iii) a transmembrane domain, and (iv) an intracellular domain. In some aspects, the present disclosure provides a CAR (or a polynucleotide encoding a CAR), wherein the CAR comprises (i) an antigen binding domain that specifically binds to mesothelin (e.g., an anti-mesothelin scFv), (ii) a hinge region comprising the amino acid sequence shown in SEQ ID NO: 30, (iii) a transmembrane domain, and (iv) an intracellular domain.

[0169] In some aspects, the hinge comprises a CD8 hinge. In some aspects, the CAR comprises a hinge comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 32 (Table 3). In some aspects, the CAR comprises a hinge comprising an amino acid sequence shown in SEQ ID NO: 32.

[0170] Therefore, in some aspects, the present disclosure provides a CAR (or a polynucleotide encoding a CAR), wherein the CAR comprises (i) an antigen binding domain that specifically binds to mesothelin (e.g., an anti-mesothelin scFv), (ii) a hinge region comprising a hinge region of CD8, (iii) a transmembrane domain, and (iv) an intracellular domain. In some aspects, the present disclosure provides a CAR (or a polynucleotide encoding a CAR), wherein the CAR comprises (i) an antigen binding domain that specifically binds to mesothelin (e.g., an anti-mesothelin scFv), (ii) a hinge region comprising an amino acid sequence shown in SEQ ID NO: 32, (iii) a transmembrane domain, and (iv) an intracellular domain.

[0171] In some aspects, CAR also includes a transmembrane domain. The transmembrane domain may be derived from a natural or recombinant source. When the source is natural, the domain may be derived from any membrane-bound protein or transmembrane protein. In some aspects, whenever the CAR of the present disclosure has been bound to a target, the transmembrane domain is capable of signaling to the intracellular domain.

[0172] In some aspects, the transmembrane domain can include at least the transmembrane domain of each of the following: for example, CD8, KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, IL2Rβ, IL2Rγ, IL7Rα, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a , LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1(CD226), SLAMF4(CD244, 2B4), CD84, CD96(Tactile), CEACAM1, CRTAM, Ly9(C D229), CD160(BY55), PSGL1, CD100(SEMA4D), SLAMF6(NTB-A, Ly108), SLAM(SLAMF1, CD150, IPO-3), BLAME(SLAMF8), SELPLG(CD162), LTBR, ​​PAG / Cbp, NKG2D, NKG2C or CD19.

[0173] In some aspects, the TM domain is derived from CD8, CD2, CD4, CD28, CD45, PD1, CD152, or any combination thereof. In some aspects, the TM domain is derived from CD28. In some aspects, the TM domain comprises an amino acid sequence having at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to SEQ ID NO: 31. In certain aspects, the TM domain comprises the amino acid sequence shown in SEQ ID NO: 31.

[0174] Therefore, in some aspects, the present disclosure provides a CAR (or a polynucleotide encoding a CAR), wherein the CAR comprises (i) an antigen binding domain that specifically binds to mesothelin (e.g., an anti-mesothelin scFv), (ii) a hinge region, (iii) a CD28 transmembrane domain, and (iv) an intracellular domain. In some aspects, the present disclosure provides a CAR (or a polynucleotide encoding a CAR), wherein the CAR comprises (i) an antigen binding domain that specifically binds to mesothelin (e.g., an anti-mesothelin scFv), (ii) a hinge region, (iii) a transmembrane domain comprising an amino acid sequence shown in SEQ ID NO: 31, and (iv) an intracellular domain.

[0175] In some aspects, the TM domain is derived from CD8. In some aspects, the TM domain comprises an amino acid sequence having at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to SEQ ID NO: 33. In certain aspects, the TM domain comprises the amino acid sequence shown in SEQ ID NO: 33.

[0176] Therefore, in some aspects, the present disclosure provides a CAR (or a polynucleotide encoding a CAR), wherein the CAR comprises (i) an antigen binding domain that specifically binds to mesothelin (e.g., an anti-mesothelin scFv), (ii) a hinge region, (iii) a CD8 transmembrane domain, and (iv) an intracellular domain. In some aspects, the present disclosure provides a CAR (or a polynucleotide encoding a CAR), wherein the CAR comprises (i) an antigen binding domain that specifically binds to mesothelin (e.g., an anti-mesothelin scFv), (ii) a hinge region, (iii) a transmembrane domain comprising an amino acid sequence shown in SEQ ID NO: 33, and (iv) an intracellular domain.

[0177] In some aspects, CAR also includes a costimulatory domain. In some aspects, the costimulatory domain includes the costimulatory domain of the following: 4-1BB / CD137, interleukin-2 receptor (IL-2R), interleukin-12 receptor (IL-12R), IL-7, IL-21, IL-23, IL-15, CD2, CD3, CD4, CD7, CD8, CD27, CD28, CD30, CD40, ICOS, lymphocyte function-associated antigen-1 (LFA-1), LIGHT, NKG2C, OX40, DAP10, B7-H3, CD28 (ICA) missing due to Lck binding, BTLA, GITR, HVEM, LFA-1, LIGHT, NKG2C, PD-1, TILR2, TILR4, TILR7, TILR9, Fc receptor gamma chain, Fc receptor epsilon chain, a ligand specifically bound to CD83, or any combination thereof. In some aspects, the CAR comprises a 4-1BB co-stimulatory domain.

[0178] In some aspects, the costimulatory domain comprises an amino acid sequence having at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to SEQ ID NO: 34. In certain aspects, the costimulatory domain comprises the amino acid sequence set forth in SEQ ID NO: 34.

[0179] Therefore, in some aspects, the present disclosure provides a CAR (or a polynucleotide encoding a CAR), wherein the CAR comprises (i) an antigen binding domain that specifically binds to mesothelin (e.g., an anti-mesothelin scFv), (ii) a hinge region, (iii) a transmembrane domain, (vi) a co-stimulatory domain, and (v) an intracellular signaling domain. In some aspects, the present disclosure provides a CAR (or a polynucleotide encoding a CAR), wherein the CAR comprises (i) an antigen binding domain that specifically binds to mesothelin (e.g., an anti-mesothelin scFv), (ii) a hinge region, (iii) a transmembrane domain, (vi) a 4-1BB co-stimulatory domain, and (v) an intracellular signaling domain. In some aspects, the present disclosure provides a CAR (or a polynucleotide encoding a CAR), wherein the CAR comprises (i) an antigen binding domain that specifically binds to mesothelin (e.g., an anti-mesothelin scFv), (ii) a hinge region, (iii) a transmembrane domain, (iv) a costimulatory domain comprising the amino acid sequence shown in SEQ ID NO: 34, and (v) an intracellular signaling domain.

[0180] In some aspects, CAR also includes an intracellular signaling domain. In some aspects, the intracellular signaling domain includes a CD3 ζ activation domain, a CD3 δ activation domain, a CD3 ε activation domain, a CD3 η activation domain, a CD79A activation domain, a DAP 12 activation domain, a FCER1G activation domain, a DAP10 / CD28 activation domain, a ZAP70 activation domain, or any combination thereof. In some aspects, the intracellular signaling domain includes a CD3 ζ activation domain.

[0181] In some aspects, the intracellular signaling domain comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to SEQ ID NO: 35. In certain aspects, the intracellular signaling domain comprises the sequence set forth in SEQ ID NO: 35.

[0182] Therefore, in some aspects, the present disclosure provides a CAR (or a polynucleotide encoding a CAR), wherein the CAR comprises (i) an antigen binding domain that specifically binds to mesothelin (e.g., an anti-mesothelin scFv), (ii) a hinge region, (iii) a transmembrane domain, (vi) a co-stimulatory domain, and (v) an intracellular signaling domain comprising a CD3ζ activation domain. In some aspects, the present disclosure provides a CAR (or a polynucleotide encoding a CAR), wherein the CAR comprises (i) an antigen binding domain that specifically binds to mesothelin (e.g., an anti-mesothelin scFv), (ii) a hinge region, (iii) a transmembrane domain, (iv) a co-stimulatory domain; and (v) an intracellular signaling domain comprising an amino acid sequence shown in SEQ ID NO: 35.

[0183] II.D. Armored CAR-γδ T cells

[0184] In some aspects, the engineered γδT cells (e.g., Vd1+ cells) comprise (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 14, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 15, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 16, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 17, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 18, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 19; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 30; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 31; NO:31 has an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:36. The amino acid sequence shown in ID NO: 1 has an amino acid sequence with at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity. In some aspects, the engineered γδT cells do not contain IL-15Rα polypeptide or IL-15 polypeptide.

[0185] In some aspects, the engineered γδT cells (e.g., Vd1+ cells) comprise (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 14, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 15, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 16, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 17, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 18, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 19; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 30; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 31; NO:31 has an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:36. ID NO:1 has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:1; (ii) a linker comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4. The amino acid sequence set forth in NO:3 has an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity;and wherein the IL-15 polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 2. ;

[0186] In some aspects, the engineered γδ T cells (e.g., Vd1+ cells) comprise (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 20, and a VL comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 21; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 30; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 31. NO:31 has an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:36. NO:1 has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:1; (ii) a linker comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4. The amino acid sequence set forth in NO:3 has an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity;and wherein the IL-15 polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 2. ;

[0187] In some aspects, the engineered γδT cells (e.g., Vd1+ cells) comprise (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 14, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 15, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 16, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 17, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 18, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 19; (ii) a hinge region comprising the amino acid sequence shown in SEQ ID NO: 30; (iii) a transmembrane domain comprising the amino acid sequence shown in SEQ ID NO: 31; (iv) a costimulatory domain comprising the amino acid sequence shown in SEQ ID NO: 34; and (v) a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 35. NO:35; and (B) armored protein, comprising (i) an IL-2Rβ polypeptide comprising the amino acid sequence shown in SEQ ID NO:1; (ii) a linker comprising the amino acid sequence shown in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises the amino acid sequence shown in SEQ ID NO:3; and wherein the IL-15 polypeptide comprises the amino acid sequence shown in SEQ ID NO:2.

[0188] In some aspects, the engineered γδT cells (e.g., Vd1+ cells) comprise (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises a VH comprising the amino acid sequence shown in SEQ ID NO: 20 and a VL comprising the amino acid sequence shown in SEQ ID NO: 21; (ii) a hinge region comprising the amino acid sequence shown in SEQ ID NO: 30; (iii) a transmembrane domain comprising the amino acid sequence shown in SEQ ID NO: 31; (iv) a co-stimulatory domain comprising the amino acid sequence shown in SEQ ID NO: 34; and (v) an intracellular signaling domain comprising the amino acid sequence shown in SEQ ID NO: 35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising the amino acid sequence shown in SEQ ID NO: 15; (ii) a linker comprising the amino acid sequence shown in SEQ ID NO: 4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3; and wherein the IL-15 polypeptide comprises SEQ The amino acid sequence shown in ID NO:2

[0189] In some aspects, the engineered γδT cells (e.g., Vd1+ cells) comprise (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 14, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 15, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 16, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 17, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 18, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 19; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 32; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 32; NO:33 having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:36. The amino acid sequence shown in ID NO: 1 has an amino acid sequence with at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity. In some aspects, the engineered γδT cells do not contain IL-15Rα polypeptide or IL-15 polypeptide.

[0190] In some aspects, the engineered γδT cells (e.g., Vd1+ cells) comprise (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 14, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 15, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 16, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 17, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 18, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 19; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 32; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 32; NO:33 having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:36. ID NO:1 has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:1; (ii) a linker comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4. The amino acid sequence set forth in NO:3 has an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity;and wherein the IL-15 polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 2. ;

[0191] In some aspects, the engineered γδ T cells (e.g., Vd1+ cells) comprise (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 20, and a VL comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 21; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 32; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: NO:33 having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:36. NO:1 has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:1; (ii) a linker comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4. The amino acid sequence set forth in NO:3 has an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity;and wherein the IL-15 polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 2. ;

[0192] In some aspects, the engineered γδT cells (e.g., Vd1+ cells) comprise (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 14, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 15, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 16, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 17, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 18, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 19; (ii) a hinge region comprising the amino acid sequence shown in SEQ ID NO: 32; (iii) a transmembrane domain comprising the amino acid sequence shown in SEQ ID NO: 33; (iv) a costimulatory domain comprising the amino acid sequence shown in SEQ ID NO: 34; and (v) a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 35. NO:35; and (B) armored protein, comprising (i) an IL-2Rβ polypeptide comprising the amino acid sequence shown in SEQ ID NO:1; (ii) a linker comprising the amino acid sequence shown in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises the amino acid sequence shown in SEQ ID NO:3; and wherein the IL-15 polypeptide comprises the amino acid sequence shown in SEQ ID NO:2.

[0193] In some aspects, the engineered γδT cells (e.g., Vd1+ cells) comprise (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises a VH comprising the amino acid sequence shown in SEQ ID NO: 20 and a VL comprising the amino acid sequence shown in SEQ ID NO: 21; (ii) a hinge region comprising the amino acid sequence shown in SEQ ID NO: 32; (iii) a transmembrane domain comprising the amino acid sequence shown in SEQ ID NO: 33; (iv) a co-stimulatory domain comprising the amino acid sequence shown in SEQ ID NO: 34; and (v) an intracellular signaling domain comprising the amino acid sequence shown in SEQ ID NO: 35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising the amino acid sequence shown in SEQ ID NO: 1; (ii) a linker comprising the amino acid sequence shown in SEQ ID NO: 4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3; and wherein the IL-15 polypeptide comprises the amino acid sequence shown in SEQ ID NO: The amino acid sequence shown in NO:2.

[0194] In some aspects, the engineered γδT cells (e.g., Vd1+ cells) comprise (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 22, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 23, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 24, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 25, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 26, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 27; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 30; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 31; NO:31 has an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:36. The amino acid sequence shown in ID NO: 1 has an amino acid sequence with at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity. In some aspects, the engineered γδT cells do not contain IL-15Rα polypeptide or IL-15 polypeptide.

[0195] In some aspects, the engineered γδT cells (e.g., Vd1+ cells) comprise (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 22, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 23, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 24, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 25, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 26, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 27; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 30; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 31; NO:31 has an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:36. ID NO:1 has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:1; (ii) a linker comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4. The amino acid sequence set forth in NO:3 has an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity;and wherein the IL-15 polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 2. ;

[0196] In some aspects, the engineered γδ T cells (e.g., Vd1+ cells) comprise (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 28, and a VL comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 29; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 30; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 31. NO:31 has an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:36. NO:1 has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:1; (ii) a linker comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4. The amino acid sequence set forth in NO:3 has an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity;and wherein the IL-15 polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 2. ;

[0197] In some aspects, the engineered γδT cells (e.g., Vd1+ cells) comprise (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 22, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 23, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 24, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 25, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 26, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 27; (ii) a hinge region comprising the amino acid sequence shown in SEQ ID NO: 30; (iii) a transmembrane domain comprising the amino acid sequence shown in SEQ ID NO: 31; (iv) a costimulatory domain comprising the amino acid sequence shown in SEQ ID NO: 34; and (v) a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 35. NO:35; and (B) armored protein, comprising (i) an IL-2Rβ polypeptide comprising the amino acid sequence shown in SEQ ID NO:1; (ii) a linker comprising the amino acid sequence shown in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises the amino acid sequence shown in SEQ ID NO:3; and wherein the IL-15 polypeptide comprises the amino acid sequence shown in SEQ ID NO:2.

[0198] In some aspects, the engineered γδT cells (e.g., Vd1+ cells) comprise (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises a VH comprising the amino acid sequence shown in SEQ ID NO: 28 and a VL comprising the amino acid sequence shown in SEQ ID NO: 29; (ii) a hinge region comprising the amino acid sequence shown in SEQ ID NO: 30; (iii) a transmembrane domain comprising the amino acid sequence shown in SEQ ID NO: 31; (iv) a co-stimulatory domain comprising the amino acid sequence shown in SEQ ID NO: 34; and (v) an intracellular signaling domain comprising the amino acid sequence shown in SEQ ID NO: 35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising the amino acid sequence shown in SEQ ID NO: 15; (ii) a linker comprising the amino acid sequence shown in SEQ ID NO: 4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3; and wherein the IL-15 polypeptide comprises SEQ The amino acid sequence shown in ID NO:2.

[0199] In some aspects, the engineered γδT cells (e.g., Vd1+ cells) comprise (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 22, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 23, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 24, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 25, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 26, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 27; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 32; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 32. NO:33 having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:36. The amino acid sequence shown in ID NO: 1 has an amino acid sequence with at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity. In some aspects, the engineered γδT cells do not contain IL-15Rα polypeptide or IL-15 polypeptide.

[0200] In some aspects, the engineered γδT cells (e.g., Vd1+ cells) comprise (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 22, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 23, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 24, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 25, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 26, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 27; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 32; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 32. NO:33 having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:36. ID NO:1 has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:1; (ii) a linker comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4. The amino acid sequence set forth in NO:3 has an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity;and wherein the IL-15 polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 2. ;

[0201] In some aspects, the engineered γδ T cells (e.g., Vd1+ cells) comprise (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 28, and a VL comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 29; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 32; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: NO:33 having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:36. NO:1 has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:1; (ii) a linker comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4. The amino acid sequence set forth in NO:3 has an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity;and wherein the IL-15 polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 2. ;

[0202] In some aspects, the engineered γδT cells (e.g., Vd1+ cells) comprise (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 22, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 23, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 24, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 25, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 26, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 27; (ii) a hinge region comprising the amino acid sequence shown in SEQ ID NO: 32; (iii) a transmembrane domain comprising the amino acid sequence shown in SEQ ID NO: 33; (iv) a costimulatory domain comprising the amino acid sequence shown in SEQ ID NO: 34; and (v) a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 35. NO:35; and (B) armored protein, comprising (i) an IL-2Rβ polypeptide comprising the amino acid sequence shown in SEQ ID NO:1; (ii) a linker comprising the amino acid sequence shown in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises the amino acid sequence shown in SEQ ID NO:3; and wherein the IL-15 polypeptide comprises the amino acid sequence shown in SEQ ID NO:2.

[0203] In some aspects, the engineered γδT cells (e.g., Vd1+ cells) comprise (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises a VH comprising the amino acid sequence shown in SEQ ID NO: 28 and a VL comprising the amino acid sequence shown in SEQ ID NO: 29; (ii) a hinge region comprising the amino acid sequence shown in SEQ ID NO: 32; (iii) a transmembrane domain comprising the amino acid sequence shown in SEQ ID NO: 33; (iv) a co-stimulatory domain comprising the amino acid sequence shown in SEQ ID NO: 34; and (v) an intracellular signaling domain comprising the amino acid sequence shown in SEQ ID NO: 35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising the amino acid sequence shown in SEQ ID NO: 1; (ii) a linker comprising the amino acid sequence shown in SEQ ID NO: 4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3; and wherein the IL-15 polypeptide comprises the amino acid sequence shown in SEQ ID NO: The amino acid sequence shown in NO:2.

[0204] III. Transduction Methods

[0205] In one aspect, the present invention provides a method for producing an engineered γδT cell population by transducing a γδT cell (e.g., Vδ1T cell, Vδ2T cell and / or non-Vδ1 / Vδ2T cell) population with a polynucleotide, such as a viral vector, such as a retroviral vector. The method includes providing a γδT cell population; and transducing the γδT cell population with a polynucleotide encoding IL-15Rβ, thereby producing a γδT cell population expressing recombinant IL-15Rβ. The method may also include transducing a starting γδT cell population with a polynucleotide encoding an IL-15 receptor α subunit or a fragment thereof. In other embodiments, the method includes producing a γδT cell population expressing recombinant IL-15Rβ and IL-15 or a variant thereof. The method includes providing a γδT cell population; transducing the γδT cell population with a polynucleotide encoding IL-15Rβ; and transducing the γδT cell population with a polynucleotide encoding IL-15 or a variant thereof, thereby producing a γδT cell population expressing recombinant IL-15Rβ and IL-15 or a variant thereof. The method may include transducing a starting γδT cell population with a polynucleotide encoding an IL-15 receptor α subunit or a fragment thereof. The method described herein may also include transducing cells with a polynucleotide encoding a CAR.

[0206] In another aspect, the present invention provides a method for producing an engineered γδT cell population by the following steps: providing a starting γδT cell population, sensitizing the γδT cells in the absence of a viral vector, and culturing the sensitized γδT cell population in the presence of a viral vector effective to transduce at least 3% (e.g., at least 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 99% or substantially all) of the sensitized γδT cells. In some embodiments, the sensitized γδT cell population is cultured in the presence of a viral vector effective to transduce at least 5% of the sensitized γδT cells. In some embodiments, the primed γδ T cell population is cultured in the presence of an amount of viral vector effective to transduce at least 20% of the primed γδ T cells.

[0207] Sensitized γδT cells can be obtained by culturing a starting γδT cell population in the absence of a viral vector. For example, a starting γδT cell population can be cultured for at least 1 hour (e.g., at least 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days or longer, for example, about 1 hour to about 14 days, about 6 hours to about 14 days, about 1 day to about 14 days, about 2 days to about 14 days, about 5 days to about 14 days, about 7 days to about 14 days, about 5 days to about 10 days, about 5 days to about 7 days, or about 7 days to about 10 days) of the first culture period. When sensitized γδT cells are obtained after culturing the cells, for example, in the absence of a viral vector, the sensitized γδT cells can be further cultured for a second culture period of at least 1 day (e.g., at least 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days or longer, for example, about 1 day to about 14 days, about 2 days to about 14 days, about 5 days to about 14 days, about 7 days to about 14 days, about 5 days to about 10 days, about 5 days to about 7 days, or about 7 days to about 10 days). The second culture period may be about 1 day to about 14 days (e.g., about 3 days to about 14 days, about 3 days to about 12 days, about 4 days to about 1 day, about 5 days to about 10 days, or about 5 days to about 7 days).

[0208] In some embodiments, the viral vector is cultured with sensitized γδT cells at a multiplicity of infection (MOI) of no more than about 10, for example, no more than about 9, 8, 7, 6, 5, 4, 3, 2, 1, 0.5 or 0.25. In some embodiments, the viral vector is cultured with sensitized γδT cells at a multiplicity of infection (MOI) of no more than about 5. In some embodiments, the viral vector is cultured with sensitized γδT cells at a multiplicity of infection (MOI) of no more than about 4. In some embodiments, the viral vector is cultured with sensitized γδT cells at a multiplicity of infection (MOI) of no more than about 3. In some embodiments, the viral vector is cultured with sensitized γδT cells at a multiplicity of infection (MOI) of no more than about 2. In some embodiments, the viral vector is cultured with sensitized γδT cells at a multiplicity of infection (MOI) of no more than about 1. In some embodiments, the viral vector is cultured with sensitized γδT cells at a multiplicity of infection (MOI) of no more than about 0.5. In some embodiments, the viral vector is cultured with sensitized γδT cells at a multiplicity of infection (MOI) of no more than about 0.25. In some embodiments, the viral vector is cultured with sensitized γδT cells at a multiplicity of infection (MOI) of about 0.25 to about 10 (e.g., about 0.5 to about 10, about 1 to about 10, or about 1 to about 5).

[0209] In some embodiments, transduction of γδT cells includes the use of a transduction enhancer to increase transduction efficiency. Suitable transduction enhancers include, for example, carrier fusion proteins, sperm cells and / or fibronectin. The method may include contacting γδT cells with a transduction enhancer during culture. In some embodiments, the method further includes contacting the cells with nevirapine. In some embodiments, transduction of γδT cells includes supplementing the culture medium with IL-15, which can increase the γδT cell expression of the virus entry receptor ASCT-2 of the β-retroviral pseudotyped virus vector.

[0210] IV. Viral Vectors

[0211] Compositions and methods described herein include using viral vectors to efficiently transduce γδT cells. The viral genome provides a rich source of vectors that can be used to efficiently deliver exogenous genes to mammalian cells. The viral genome is a particularly useful vector for gene delivery, because the polynucleotides contained in such genomes are usually incorporated into the nuclear genome of mammalian cells by universal or special transduction. These processes occur as part of the natural viral replication cycle and do not require the addition of proteins or reagents to induce gene integration. Examples of viral vectors include retroviruses (e.g., Retroviridae virus vectors). Examples of retroviruses are avian leukemia-sarcoma, avian C-type viruses, mammalian C-type, B-type viruses, D-type viruses, oncoviruses, HTLV-BLV groups, slow viruses, alpha retroviruses, beta retroviruses, gamma retroviruses, foamy viruses (Coffin, JM, Retroviridae: The viruses and their replication, Virology, 3rd edition (Lippincott-Raven, Philadelphia, (1996))). Other examples are murine leukemia virus (MLV), murine sarcoma virus, mouse mammary tumor virus, bovine leukemia virus, feline leukemia virus, feline sarcoma virus, avian leukemia virus, human T-cell leukemia virus, baboon endogenous virus (BaEV), gibbon ape leukemia virus, Mason Pfizer monkey virus, simian immunodeficiency virus, simian sarcoma virus, Rous sarcoma virus and lentiviruses.

[0212] IV.A. Retroviral Vectors

[0213] In some cases, the viral vector used in the methods and compositions described herein is a retroviral vector. One type of retroviral vector that can be used in the methods and compositions described herein is a lentiviral vector. Lentiviral vectors (LV), a subset of retroviruses, transduce a wide range of dividing and non-dividing cell types with high efficiency, thereby conferring stable, long-term expression of transgenes. An overview of optimization strategies for packaging and transducing LVs is provided in Delenda, The Journal of Gene Medicine 6: S125, 2004, the disclosure of which is incorporated herein by reference.

[0214] Gene transfer techniques based on lentiviruses rely on the in vitro production of recombinant lentiviral particles with a highly deleted viral genome in which the transgene of interest is housed. Specifically, recombinant lentiviruses are recovered via trans-coexpression in a permissive cell line of: (1) a packaging construct, i.e., a vector expressing the Gag-Pol precursor together with Rev (alternatively expressed in trans); (2) a vector expressing an envelope protein, usually of a heterologous nature; and (3) a transfer vector, which consists of a viral cDNA that has lost all open reading frames but retains the sequences required for replication, encapsidation, and expression, into which the sequence to be expressed is inserted.

[0215] LV used in the methods and compositions described herein may include one or more of the following: 5'-long terminal repeat (LTR), HIV signal sequence, HIV Psi signal 5'-splicing site (SD), delta-GAG element, Rev response element (RRE), 3'-splicing site (SA), elongation factor (EF) 1-alpha promoter and 3'-self-inactivating LTR (SIN-LTR). Lentiviral vectors optionally include a central polypurine tract (cPPT) and a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), as described in US 6,136,597, the disclosure of which is incorporated herein by reference for WPRE. Lentiviral vectors may also include a pHR' backbone, which may include, for example, as provided below.

[0216] Lu et al., Journal of Gene Medicine 6: 963, 2004 described LentigenLV can be used to express DNA molecules and / or transduce cells. The LV used in the methods and compositions described herein can be 5'-long terminal repeats (LTR), HIV signal sequences, HIV Psi signal 5'-splicing sites (SD), delta-GAG elements, Rev response elements (RRE), 3'-splicing sites (SA), elongation factor (EF) 1-alpha promoter and 3'-self-inactivating LTR (SIN-LTR). It is readily apparent to those skilled in the art that optionally one or more of these regions are replaced by another region that performs similar functions.

[0217] Enhancer elements can be used to increase the expression of modified DNA molecules or improve the efficiency of lentiviral integration. The LV used in the methods and compositions described herein may include a nef sequence. The LV used in the methods and compositions described herein may include a cPPT sequence that enhances vector integration. The cPPT serves as a second source for (+)-chain DNA synthesis and introduces partial chain overlap in the middle of its native HIV genome. The introduction of the cPPT sequence in the transfer vector backbone greatly increases the total amount of genomes transported to the nucleus and integrated into the DNA of the target cell. The LV used in the methods and compositions described herein may include a woodchuck post-transcriptional regulatory element (WPRE). The WPRE acts at the transcriptional level by promoting nuclear export of transcripts and / or by increasing the polyadenylation efficiency of nascent transcripts, thereby increasing the total amount of mRNA in the cell. In vitro and in vivo, the addition of the WPRE to the LV results in substantial improvements in the expression level of transgenes from several different promoters. The LV used in the methods and compositions described herein may include both cPPT sequences and WPRE sequences. The vector may also include an IRES sequence that allows multiple polypeptides to be expressed from a single promoter.

[0218] In addition to IRES sequences, other elements that allow expression of multiple polypeptides are also available. The vectors used in the methods and compositions described herein may include multiple promoters that allow expression of more than one polypeptide. The vectors used in the methods and compositions described herein may include protein cleavage sites that allow expression of more than one polypeptide. Examples of protein cleavage sites that allow expression of more than one polypeptide are described in the following literature: Klump et al., Gene Ther.; 8:811, 2001; Osborn et al., Molecular Therapy 12:569, 2005; Szymczak and Vignali, Expert Opin.Biol.Ther.5:627, 2005; and Szymczak et al., Nat.Biotechnol.22:589, 2004, the disclosures of which are incorporated herein by reference because they relate to protein cleavage sites that allow expression of more than one polypeptide. It will be readily apparent to those skilled in the art that other elements that allow expression of multiple polypeptides identified in the future are available and can be used in vectors suitable for use with the compositions and methods described herein.

[0219] Other retroviral vectors (e.g., retroviral backbones) that can be used in conjunction with the compositions and methods described herein include gamma retroviral vectors. Exemplary gamma retroviral vectors are or are derived from chicken fusion virus, feline leukemia virus, Finkel-Biskis-Jinkins murine sarcoma virus, Gardner-Arnstein feline sarcoma virus, gibbon ape leukemia virus, guinea pig type C oncovirus, Hardy-Zuckerman feline sarcoma virus, Harvey murine sarcoma virus, Kirsten murine sarcoma virus, Koala retrovirus, Moloney murine sarcoma virus, murine leukemia virus, porcine type C oncovirus, reticuloendotheliosis virus, Snyder-Theilen feline sarcoma virus, Trager duck spleen necrosis virus, viper retrovirus, and woolly monkey sarcoma virus.

[0220] In certain embodiments, the viral vector backbone is derived from a lentivirus (LV). In certain embodiments, the viral vector backbone is derived from a third generation self-inactivating (SIN) lentiviral vector (LV) (e.g., HIV, SIV or EIAV). In certain embodiments, the viral vector backbone is derived from a non-self-inactivating LV (e.g.,

[0221] Other retroviral vectors (e.g., retroviral backbones) that can be used in conjunction with the compositions and methods described herein include alpharetroviral vectors. Exemplary alpharetroviral vectors are or are derived from avian cancer Millhill virus 2, avian leukosis virus, avian myeloblastosis virus, avian myelocytoma virus 29, avian sarcoma virus CT10, Fujinami sarcoma virus, Rous sarcoma virus, UR2 sarcoma virus, and Y73 sarcoma virus.

[0222] In some aspects, the viral vector comprises a polynucleotide encoding: (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 14, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 15, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 16, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 17, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 18, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 19; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 30; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 31; NO:31 has an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:36. The amino acid sequence shown in ID NO: 1 has an amino acid sequence with at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity. In some aspects, the engineered γδT cells do not contain IL-15Rα polypeptide or IL-15 polypeptide.

[0223] In some aspects, the viral vector comprises a polynucleotide encoding: (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 14, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 15, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 16, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 17, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 18, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 19; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 30; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 31; NO:31 has an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:36. ID NO:1 has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:1; (ii) a linker comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4. The amino acid sequence set forth in NO:3 has an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity;and wherein the IL-15 polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 2. ;

[0224] In some aspects, the viral vector comprises a polynucleotide encoding: (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 20, and a VL comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 21; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 30; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: NO:31 has an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:36. NO:1 has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:1; (ii) a linker comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4. The amino acid sequence set forth in NO:3 has an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity;and wherein the IL-15 polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 2. ;

[0225] In some aspects, the viral vector comprises a polynucleotide encoding: (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 14, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 15, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 16, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 17, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 18, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 19; (ii) a hinge region comprising the amino acid sequence shown in SEQ ID NO: 30; (iii) a transmembrane domain comprising the amino acid sequence shown in SEQ ID NO: 31; (iv) a costimulatory domain comprising the amino acid sequence shown in SEQ ID NO: 34; and (v) an intracellular signaling domain comprising the amino acid sequence shown in SEQ ID NO: 35; and (B) an armored protein comprising (i) a protein comprising SEQ ID NO:1; (ii) a linker comprising the amino acid sequence shown in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises the amino acid sequence shown in SEQ ID NO:3; and wherein the IL-15 polypeptide comprises the amino acid sequence shown in SEQ ID NO:2.

[0226] In some aspects, the viral vector comprises a polynucleotide encoding: (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises a VH comprising the amino acid sequence shown in SEQ ID NO: 20 and a VL comprising the amino acid sequence shown in SEQ ID NO: 21; (ii) a hinge region comprising the amino acid sequence shown in SEQ ID NO: 30; (iii) a transmembrane domain comprising the amino acid sequence shown in SEQ ID NO: 31; (iv) a co-stimulatory domain comprising the amino acid sequence shown in SEQ ID NO: 34; and (v) an intracellular signaling domain comprising the amino acid sequence shown in SEQ ID NO: 35; and (B) an armor protein comprising (i) an IL-2Rβ polypeptide comprising the amino acid sequence shown in SEQ ID NO: 1; (ii) a linker comprising the amino acid sequence shown in SEQ ID NO: 4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3; and wherein the IL-15 polypeptide comprises the amino acid sequence shown in SEQ ID NO: The amino acid sequence shown in NO:2.

[0227] In some aspects, the polynucleotide portion encoding (A) CAR is connected to the polynucleotide portion encoding (B) armored protein by the polynucleotide portion encoding the joint. In some aspects, the joint comprises a peptide bond. In some aspects, the joint comprises one or more amino acids. In some aspects, the joint is a cleavable joint. In some aspects, the joint comprises a T2A joint. In some aspects, the joint comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity with the amino acid sequence shown in SEQ ID NO:5. In some aspects, the joint comprises the amino acid sequence shown in SEQ ID NO:5.

[0228] In some aspects, the viral vector comprises a polynucleotide encoding: (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 14, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 15, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 16, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 17, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 18, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 19; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 32; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 32; NO:33 having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:36. The amino acid sequence shown in ID NO: 1 has an amino acid sequence with at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity. In some aspects, the engineered γδT cells do not contain IL-15Rα polypeptide or IL-15 polypeptide.

[0229] In some aspects, the viral vector comprises a polynucleotide encoding: (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 14, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 15, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 16, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 17, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 18, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 19; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 32; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 32; NO:33 having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:36. ID NO:1 has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:1; (ii) a linker comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4. The amino acid sequence set forth in NO:3 has an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity;and wherein the IL-15 polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 2. ;

[0230] In some aspects, the viral vector comprises a polynucleotide encoding: (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 20, and a VL comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 21; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 32; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: NO:33 having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:36. NO:1 has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:1; (ii) a linker comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4. The amino acid sequence set forth in NO:3 has an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity;and wherein the IL-15 polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 2. ;

[0231] In some aspects, the viral vector comprises a polynucleotide encoding: (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 14, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 15, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 16, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 17, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 18, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 19; (ii) a hinge region comprising the amino acid sequence shown in SEQ ID NO: 32; (iii) a transmembrane domain comprising the amino acid sequence shown in SEQ ID NO: 33; (iv) a costimulatory domain comprising the amino acid sequence shown in SEQ ID NO: 34; and (v) an intracellular signaling domain comprising the amino acid sequence shown in SEQ ID NO: 35; and (B) an armored protein comprising (i) a protein comprising SEQ ID NO:1; (ii) a linker comprising the amino acid sequence shown in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises the amino acid sequence shown in SEQ ID NO:3; and wherein the IL-15 polypeptide comprises the amino acid sequence shown in SEQ ID NO:2.

[0232] In some aspects, the viral vector comprises a polynucleotide encoding: (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises a VH comprising the amino acid sequence shown in SEQ ID NO: 20 and a VL comprising the amino acid sequence shown in SEQ ID NO: 21; (ii) a hinge region comprising the amino acid sequence shown in SEQ ID NO: 32; (iii) a transmembrane domain comprising the amino acid sequence shown in SEQ ID NO: 33; (iv) a co-stimulatory domain comprising the amino acid sequence shown in SEQ ID NO: 34; and (v) an intracellular signaling domain comprising the amino acid sequence shown in SEQ ID NO: 35; and (B) an armor protein comprising (i) an IL-2Rβ polypeptide comprising the amino acid sequence shown in SEQ ID NO: 1; (ii) a linker comprising the amino acid sequence shown in SEQ ID NO: 4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3; and wherein the IL-15 polypeptide comprises the amino acid sequence shown in SEQ ID NO: The amino acid sequence shown in NO:2.

[0233] In some aspects, the polynucleotide portion encoding (A) CAR is connected to the polynucleotide portion encoding (B) armored protein through the polynucleotide portion encoding the joint. In some aspects, the joint comprises a peptide bond. In some aspects, the joint comprises one or more amino acids. In some aspects, the joint is a cleavable joint. In some aspects, the joint comprises a T2A joint. In some aspects, the joint comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity with the amino acid sequence shown in SEQ ID NO:5. In some aspects, the joint comprises the amino acid sequence shown in SEQ ID NO:5

[0234] In some aspects, the viral vector comprises a polynucleotide encoding: (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 22, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 23, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 24, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 25, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 26, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 27; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 30; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 31; NO:31 has an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:36. The amino acid sequence shown in ID NO: 1 has an amino acid sequence with at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity. In some aspects, the engineered γδT cells do not contain IL-15Rα polypeptide or IL-15 polypeptide.

[0235] In some aspects, the viral vector comprises a polynucleotide encoding: (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 22, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 23, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 24, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 25, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 26, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 27; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 30; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 31; NO:31 has an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:36. ID NO:1 has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:1; (ii) a linker comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4. The amino acid sequence set forth in NO:3 has an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity;and wherein the IL-15 polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 2. ;

[0236] In some aspects, the viral vector comprises a polynucleotide encoding: (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 28, and a VL comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 29; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 30; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: NO:31 has an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:36. NO:1 has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:1; (ii) a linker comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4. The amino acid sequence set forth in NO:3 has an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity;and wherein the IL-15 polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 2. ;

[0237] In some aspects, the viral vector comprises a polynucleotide encoding: (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 22, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 23, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 24, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 25, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 26, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 27; (ii) a hinge region comprising the amino acid sequence shown in SEQ ID NO: 30; (iii) a transmembrane domain comprising the amino acid sequence shown in SEQ ID NO: 31; (iv) a costimulatory domain comprising the amino acid sequence shown in SEQ ID NO: 34; and (v) an intracellular signaling domain comprising the amino acid sequence shown in SEQ ID NO: 35; and (B) an armored protein comprising (i) a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 22, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 23, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 24, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 25, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 26, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 27. NO:1; (ii) a linker comprising the amino acid sequence shown in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises the amino acid sequence shown in SEQ ID NO:3; and wherein the IL-15 polypeptide comprises the amino acid sequence shown in SEQ ID NO:2.

[0238] In some aspects, the viral vector comprises a polynucleotide encoding: (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises a VH comprising the amino acid sequence shown in SEQ ID NO: 28 and a VL comprising the amino acid sequence shown in SEQ ID NO: 29; (ii) a hinge region comprising the amino acid sequence shown in SEQ ID NO: 30; (iii) a transmembrane domain comprising the amino acid sequence shown in SEQ ID NO: 31; (iv) a co-stimulatory domain comprising the amino acid sequence shown in SEQ ID NO: 34; and (v) an intracellular signaling domain comprising the amino acid sequence shown in SEQ ID NO: 35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising the amino acid sequence shown in SEQ ID NO: 1; (ii) a linker comprising the amino acid sequence shown in SEQ ID NO: 4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3; and wherein the IL-15 polypeptide comprises the amino acid sequence shown in SEQ ID NO: The amino acid sequence shown in NO:2.

[0239] In some aspects, the polynucleotide portion encoding (A) CAR is connected to the polynucleotide portion encoding (B) armored protein by the polynucleotide portion encoding the joint. In some aspects, the joint comprises a peptide bond. In some aspects, the joint comprises one or more amino acids. In some aspects, the joint is a cleavable joint. In some aspects, the joint comprises a T2A joint. In some aspects, the joint comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity with the amino acid sequence shown in SEQ ID NO:5. In some aspects, the joint comprises the amino acid sequence shown in SEQ ID NO:5.

[0240] In some aspects, the viral vector comprises a polynucleotide encoding: (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 22, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 23, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 24, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 25, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 26, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 27; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 32; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 32. NO:33 having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:36. The amino acid sequence shown in ID NO: 1 has an amino acid sequence with at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity. In some aspects, the engineered γδT cells do not contain IL-15Rα polypeptide or IL-15 polypeptide.

[0241] In some aspects, the viral vector comprises a polynucleotide encoding: (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 22, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 23, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 24, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 25, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 26, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 27; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 32; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 32. NO:33 having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:36. 14:15; (ii) a linker comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence of SEQ ID NO:2; (ii) a linker comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence of SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence of SEQ ID NO:4. The amino acid sequence set forth in NO:3 has an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity;and wherein the IL-15 polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 2. ;

[0242] In some aspects, the viral vector comprises a polynucleotide encoding: (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 28, and a VL comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 29; (ii) a hinge region comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: 32; (iii) a transmembrane domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO: NO:33 having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity; (iv) a costimulatory domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:34; and (v) an intracellular signaling domain comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO:36. NO:1 has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:1; (ii) a linker comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:4. The amino acid sequence set forth in NO:3 has an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity;and wherein the IL-15 polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 2. ;

[0243] In some aspects, the viral vector comprises a polynucleotide encoding: (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises: a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 22, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 23, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 24, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 25, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 26, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 27; (ii) a hinge region comprising the amino acid sequence shown in SEQ ID NO: 32; (iii) a transmembrane domain comprising the amino acid sequence shown in SEQ ID NO: 33; (iv) a costimulatory domain comprising the amino acid sequence shown in SEQ ID NO: 34; and (v) an intracellular signaling domain comprising the amino acid sequence shown in SEQ ID NO: 35; and (B) an armored protein comprising (i) a VH-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 22, a VH-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 23, a VH-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 24, a VL-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 25, a VL-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 26, and a VL-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 27. NO:1; (ii) a linker comprising the amino acid sequence shown in SEQ ID NO:4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises the amino acid sequence shown in SEQ ID NO:3; and wherein the IL-15 polypeptide comprises the amino acid sequence shown in SEQ ID NO:2.

[0244] In some aspects, the viral vector comprises a polynucleotide encoding: (A) a CAR comprising (i) an antigen binding domain that specifically binds to human mesothelin, wherein the antigen binding domain comprises a VH comprising the amino acid sequence shown in SEQ ID NO: 28 and a VL comprising the amino acid sequence shown in SEQ ID NO: 29; (ii) a hinge region comprising the amino acid sequence shown in SEQ ID NO: 32; (iii) a transmembrane domain comprising the amino acid sequence shown in SEQ ID NO: 33; (iv) a co-stimulatory domain comprising the amino acid sequence shown in SEQ ID NO: 34; and (v) an intracellular signaling domain comprising the amino acid sequence shown in SEQ ID NO: 35; and (B) an armored protein comprising (i) an IL-2Rβ polypeptide comprising the amino acid sequence shown in SEQ ID NO: 1; (ii) a linker comprising the amino acid sequence shown in SEQ ID NO: 4; and (iii) an IL-15Rα polypeptide tethered to an IL-15 polypeptide; wherein the IL-15Rα polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3; and wherein the IL-15 polypeptide comprises the amino acid sequence shown in SEQ ID NO: The amino acid sequence shown in NO:2.

[0245] In some aspects, the polynucleotide portion encoding (A) CAR is connected to the polynucleotide portion encoding (B) armored protein by the polynucleotide portion encoding the joint. In some aspects, the joint comprises a peptide bond. In some aspects, the joint comprises one or more amino acids. In some aspects, the joint is a cleavable joint. In some aspects, the joint comprises a T2A joint. In some aspects, the joint comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity with the amino acid sequence shown in SEQ ID NO:5. In some aspects, the joint comprises the amino acid sequence shown in SEQ ID NO:5.

[0246] V. Methods for Harvesting and Expanding γδ T Cells

[0247] Engineered γδT cells can be expanded in the presence of cytokines (e.g., IL-15, IL-2) or in the absence of exogenous IL-2 or IL-15. In some embodiments, the cells are expanded in the presence of exogenous IL-15. In some embodiments, the cells express secreted IL-15 and do not require exogenous IL-15 for expansion. In some embodiments, the method includes expanding the γδT cell population in the presence of exogenous IL-2.

[0248] In one aspect, the present invention provides a method of expanding γδT cells by the following steps: providing a population of γδT cells expressing IL-15Rβ; and culturing the population of γδT cells in the presence of exogenous IL-2 and / or IL-15 or variants thereof.

[0249] In another aspect, the present invention provides a method for expanding γδT cells by the following steps: providing a population of γδT cells expressing IL-15Rβ and IL-15 or a variant thereof; and culturing the γδT cells, wherein IL-15 or a variant thereof expands the population of γδT cells.

[0250] The engineered γδT cells of the present invention may be derived from any suitable autologous or allogeneic γδT cells or populations thereof. In some embodiments, suitable γδT cells used as a source of engineered γδT cells of the present invention include Vδ1 cells, Vδ2 cells, Vδ3 cells, Vδ5 cells, and Vδ8 cells. In some embodiments, the engineered γδT cell population is derived from a Vδ1 cell population or a Vδ2 cell population.

[0251] For example, provided herein is a method for isolating and amplifying Vδ1 cells from non-hematopoietic tissues such as skin or intestines. In other embodiments, suitable γδT cells may be derived from blood (e.g., peripheral blood). Methods for isolating and amplifying Vδ1 cells from blood include, for example, those described in U.S. Patent No. 9,499,788, International Patent Publication No. WO 2016 / 198480, and UK Patent Application No. 2204926.6, each of which is incorporated herein by reference in its entirety. In some embodiments, suitable γδT cells may be derived from tumor tissue (e.g., tumor-infiltrated γδT cells). Alternatively, suitable γδT cells that may be engineered to express transgenics may be derived from non-hematopoietic tissues according to the methods described below.

[0252] VA Isolation and Expansion of γδ T Cells from Blood

[0253] In some embodiments, the engineered γδT cells of the present invention are derived from the blood (eg, peripheral blood) of a subject. For example, the engineered γδT cells may be derived from blood-derived Vδ2 cells or blood-derived Vδ1 cells.

[0254] In some embodiments, peripheral blood mononuclear cells (PBMC) can be obtained from a subject according to any suitable method known in the art. PBMC can be cultured for one to two weeks in the presence of IL-2 in the presence of aminobisphosphonates (e.g., zoledronic acid), synthetic phosphoantigens (e.g., bromohydrin pyrophosphate; BrHPP), 2M3B1PP or 2-methyl-3-butenyl-1-pyrophosphate to produce an enriched Vδ2 cell population. Alternatively, fixed anti-TCRγδ (e.g., pan-TCRγδ) can induce preferential expansion of Vδ2 cells from a PBMC population in the presence of IL-2, for example, for about 14 days. In some embodiments, preferential expansion of Vδ2 cells from PBMCs can be achieved after culturing fixed anti-CD3 antibodies (e.g., OKT3) in the presence of IL-2 and IL-4. In some embodiments, the aforementioned culture is maintained for about seven days before subculturing in soluble anti-CD3, IL-2, and IL-4. Alternatively, artificial antigen presenting cells can be used to promote preferential expansion of γδT cells such as Vδ2 cells. For example, γδT cells derived from PBMCs cultured in the presence of irradiated aAPC, IL-2, and / or IL-21 can be expanded to produce a γδT cell population, including a high proportion of Vδ2 cells, a moderate proportion of Vδ1 cells, and some double negative cells. In some embodiments of the aforementioned method, PBMCs may be pre-enriched or post-enriched (e.g., via positive selection with TCRγδ specific reagents or negative selection of TCRαβ specific reagents). Such methods and other suitable methods for amplifying γδT cells such as Vδ2 cells are described in detail by Deniger et al., Frontiers in Immunology 5, 636: 1-10, 2014, which are incorporated herein by reference in their entirety.

[0255] In some embodiments, Vδ1T cells may be engineered to express a transgene (e.g., a heterologous targeting construct). Any suitable method for obtaining a Vδ1T cell population may be used. For example, Almeida et al. (Clinical Cancer Research, 22, 23; 5795-5805, 2016), which is incorporated herein by reference in its entirety, provides a suitable method for obtaining a Vδ1T cell population that can be engineered to express a heterologous targeting construct described herein. For example, in some embodiments, PBMCs are pre-enriched using magnetic bead sorting, which can produce greater than 90% γδT cells. These cells can be cultured in a breathable bioreactor bag in the presence of one or more factors (e.g., TCR agonists, co-receptor agonists and / or cytokines, such as IL-4, IL-15 and / or IFN-γ) for up to 21 days or longer. Variations of this method and other methods for obtaining Vδ1T cells are suitable as part of the present invention. For example, blood-derived Vδ1 T cells can alternatively be obtained using methods such as those described in U.S. Pat. No. 9,499,788 and International Patent Publication No. WO 2016 / 198480, each of which is incorporated herein by reference in its entirety.

[0256] VB Isolation and expansion of non-hematopoietic tissue-resident γδ T cells from non-hematopoietic tissues

[0257] Non-hematopoietic tissue-resident γδT cells obtained as described below may be suitable carriers of the transgenes described herein because they may exhibit good tumor penetration and retention capabilities. More detailed methods for isolating and expanding non-hematopoietic tissue-resident γδT cells can be found in, for example, PCT Publication Nos. WO 2020 / 095058, WO 2020 / 095059, WO 2017 / 072367, and GB Application No. 2006989.4, each of which is incorporated herein by reference in its entirety.

[0258] Non-hematopoietic tissue-resident γδT cells (e.g., skin-derived γδT cells and / or non-Vδ2T cells, e.g., Vδ1T cells and / or DN T cells) can be isolated from any human or non-human animal non-hematopoietic tissue, which can be removed from a patient to obtain cells suitable for engineering according to the methods of the present invention. In some embodiments, the non-hematopoietic tissue from which γδT cells are derived and expanded is skin (e.g., human skin), which can be obtained by methods known in the art. In some embodiments, the skin is obtained by puncture biopsy. Alternatively, the methods for separating and expanding γδT cells provided herein can be applied to the gastrointestinal tract (e.g., colon), breast, lung, prostate, liver, spleen, and pancreas. γδT cells may also reside in human cancer tissues, e.g., tumors of the breast or prostate. In some embodiments, γδT cells may be derived from human cancer tissues (e.g., solid tumor tissues). In other embodiments, γδT cells may be derived from non-hematopoietic tissues other than human cancer tissues (e.g., tissues without a large number of tumor cells). For example, the γδ T cells can be derived from an area of ​​skin (eg, healthy skin) that is separate from nearby or adjacent cancer tissue.

[0259] The γδT cells that dominate in the blood are mainly Vδ2T cells, while the γδT cells that dominate in non-hematopoietic tissues are mainly Vδ1T cells, so that Vδ1T cells account for about 70%-80% of the γδT cell population resident in non-hematopoietic tissues. However, some Vδ2T cells are also found in non-hematopoietic tissues such as the intestine, where the cells may account for about 10%-20% of γδT cells. Some γδT cells residing in non-hematopoietic tissues express neither Vδ1 nor Vδ2TCR, and are named double negative (DN) γδT cells. These DNγδT cells may be mainly T cells expressing Vδ3, and a few are T cells expressing Vδ5. Therefore, the γδT cells that usually reside in non-hematopoietic tissues and are expanded by the method of the present invention are preferably non-Vδ2T cells, for example, Vδ1T cells, and contain a smaller number of DNγδT cells.

[0260] In some embodiments, a key step is to artificially separate non-hematopoietic tissue-resident T cells (e.g., within a mixed lymphocyte population, which may, for example, include αβ cells, natural killer (NK) cells, B cells, and γδ2 and non-γδ2 T cells) from non-hematopoietic cells (e.g., stromal cells, particularly fibroblasts) of the tissue from which the T cells were obtained, for example, after several days or weeks of culture. This allows for the preferential and rapid expansion of non-hematopoietic tissue-derived Vδ1 T cells and DNγδ T cells in the following days and weeks.

[0261] In general, non-hematopoietic tissue-resident γδT cells are able to spontaneously expand after removing physical contact with stromal cells (e.g., skin fibroblasts). Therefore, the scaffold-based culture method described above can be used to induce such separation, thereby causing γδT cells to de-repress to trigger expansion. Therefore, in some embodiments, during the expansion step, there is no substantial TCR pathway activation (e.g., no exogenous TCR pathway activator is included in the culture). In addition, the present invention provides a method for expanding non-hematopoietic tissue-resident γδT cells, wherein the method does not involve contact with feeder cells, tumor cells and / or antigen presenting cells.

[0262] The expansion scheme involves culturing non-hematopoietic tissue-resident γδT cells in the presence of an effective mixture of biological factors that support efficient γδT cell expansion. In one embodiment, the method for expanding γδT cells includes providing a γδT cell population obtained from a non-hematopoietic tissue (e.g., a separated non-hematopoietic tissue-derived γδT cell population, e.g., a population separated according to the methods described herein) and culturing γδT cells in the presence of IL-2 and IL-15, and optionally IL-1β, IL-4 and / or IL-21. These cytokines or their analogs can effectively produce an amount of expanded γδT cell populations and a certain duration of cell culture (e.g., at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least 21 days, at least 28 days or longer, e.g., 5 days to 40 days, 7 days to 35 days, 14 days to 28 days, or about 21 days).

[0263] Many basal media suitable for priming and / or expanding γδ T cells are available, such as complete medium, OPTMIZER™, AIM-V, Iscoves medium, and RPMI-1640 (Life Technologies) and TEXMACS TM (Miltenyi Biotec). The culture medium may be supplemented with other culture medium factors, such as serum, serum proteins, and selective agents such as antibiotics. For example, in some embodiments, the culture medium includes RPMI-1640 containing 2mM glutamine, 10% FBS, 10mM HEPES (pH 7.2), 1% penicillin-streptomycin, sodium pyruvate (1mM; Life Technologies), non-essential amino acids (e.g., 100μM Gly, Ala, Asn, Asp, Glu, Pro, and Ser; 1X MEM non-essential amino acids LifeTechnologies) and 10μl / L β-mercaptoethanol. Suitably, the cells are cultured in a suitable culture medium at 37°C in a humidified atmosphere containing 5% CO2.

[0264] γδT cells can be cultured in any suitable system as described herein, including stirred tank fermenters, airlift fermenters, roller bottles, culture bags or dishes, and other bioreactors, such as hollow fiber bioreactors. The use of such systems is well known in the art. General methods and techniques for culturing lymphocytes are well known in the art.

[0265] The methods described herein may include more than one selection step, e.g., more than one depletion step. Enrichment of a T cell population by negative selection can be accomplished, for example, using a combination of antibodies to surface markers unique to the negatively selected cells. One method is cell sorting and / or selection via negative magnetic immunoadhesion or flow cytometry, which uses a mixture of monoclonal antibodies to cell surface markers present on the negatively selected cells.

[0266] VI. Transgenic

[0267] The engineered γδT cells of the present invention are engineered to express the desired transgene. γδT cells engineered to express transgenes are suitable for cancer treatment (e.g., immunotherapy). The viral vectors described herein encode transgenes, which are stably or transiently expressed in transduced γδT cells. Transgenes that can be used in combination with the compositions and methods described herein include IL-15Rβ, IL-15Rα, IL-15, or any biologically active variants, mutant proteins, or truncated fragments thereof. Other transgenes include, for example, chimeric antigen receptors (CARs). A transgene may include an internal ribosome entry site (IRES) operably linked to a transgene.

[0268] In some embodiments, γδT cells express two or more (e.g., two, three, four or more) transgenes. Each transgene can be expressed on a single polynucleotide so that they are expressed in series. Each transgene can include a joint therebetween. The joint can encode a cleavable peptide or include an IRES. The cleavable peptide can be, for example, a self-cleaving peptide, such as a 2A peptide. In some embodiments, the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide, or a T2A peptide. In some embodiments, the polynucleotide includes a different IRES for each transgene operably connected to a single polynucleotide. In some embodiments, the polynucleotide includes a single IRES for all transgenes operably connected to a single polynucleotide.

[0269] In some cases, the transgene to be expressed by the engineered γδT cells of the present invention includes a selectable marker (e.g., a reporter gene) or a suicide gene. For example, a truncated epidermal growth factor receptor (EGFR) lacking an intracellular signaling domain can be used as a transgene for in vivo depletion using anti-EGFR monoclonal antibodies when, for example, toxicity occurs. Similarly, CD20 can be used as a transgene for in vivo depletion using anti-CD20 monoclonal antibodies. Another exemplary transgene is a suicide gene that promotes drug-mediated control of the administered engineered γδT cells. In the event of an adverse event, the modified cells can be depleted from the patient's body via the use of a suicide gene. In one example, the drug binding domain is fused to a caspase 9 pro-apoptotic molecule. In some cases, the transgene is a cytosine deaminase. In some cases, the transgene is a thymidine kinase.

[0270] Additionally or alternatively, the transgene expressed by the engineered γδ T cells of the invention encodes a membrane-bound protein, such as a membrane-bound receptor (e.g., αβTCR, a natural cytotoxicity receptor (e.g., NKp30, NKp44, or NKp46), a cytokine receptor (e.g., an IL-12 receptor), and / or a chemokine receptor (e.g., a CCR2 receptor), and / or a membrane-bound ligand or cytokine (e.g., membrane-bound IL-15, membrane-bound IL-7, membrane-bound CD40L, membrane-bound 4-1BB, membrane-bound 4-1BBL, membrane-bound C CL19). Membrane-bound ligands and cytokines include natural membrane-bound ligands and cytokines (e.g., trans-presented IL-15 and 4-1BBL) and synthetic membrane-bound configurations (e.g., ligands that have been artificially fused to transmembrane proteins). Additionally or alternatively, the transgene to be expressed by the engineered γδT cells of the present invention encodes a soluble protein, such as a soluble ligand or cytokine (e.g., soluble IL-15, soluble IL-7, soluble IL-12, soluble CD40L, soluble 4-1BBL and / or soluble CCL19).

[0271] In some cases, engineered γδT cells with a transgenic encoding a CAR can be armored with additional transgenics that contribute to immunogenicity. Such armored CART cells express armor proteins, such as any of the membrane-bound or soluble proteins described herein. For example, armored proteins include membrane-bound proteins, such as membrane-bound receptors (e.g., αβTCR, natural cytotoxicity receptors (e.g., NKp30, NKp44 or NKp46), cytokine receptors (e.g., IL-12 receptor) and / or chemokine receptors (e.g., CCR2 receptor) and / or membrane-bound ligands or cytokines (e.g., membrane-bound IL-15, membrane-bound IL-7, membrane-bound CD40L, membrane-bound 4-1BB, membrane-bound 4-1BBL, membrane-bound CCL19). Additionally or alternatively, armored proteins to be expressed by the engineered γδCAR T cells of the present invention include soluble proteins, such as soluble ligands or cytokines (e.g., soluble IL-15, soluble IL-7, soluble IL-12, soluble CD40L, soluble 4-1BBL and / or soluble CCL19).

[0272] In some embodiments, the engineered γδ T cells of the invention are engineered to express one or more transgenes (e.g., one or more of any transgenes described herein) for armored γδ T cells (e.g., in the form of armored CART cells, as described in Yeku and Brentjens Biochem. Soc. Trans. 2016, 15:44, 2, 412-418, which is incorporated herein by reference in its entirety).

[0273] In some embodiments, the transgene is codon optimized.

[0274] In some embodiments, at least 3% (e.g., at least 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 99%, or substantially all) of the engineered γδ T cells (e.g., Vδ1 or Vδ2 cells) population express a transgene, e.g., IL-15Rβ, CAR, or other membrane-bound or soluble protein. In some embodiments, at least 10% (e.g., at least 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 99%, or substantially all) of a population of engineered γδ T cells (e.g., Vδ1 or Vδ2 cells) express a transgene, e.g., IL-15Rβ, CAR, or other membrane-bound or soluble protein. In some embodiments, at least 50% (e.g., at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 99% or substantially all) of the engineered γδT cells (e.g., Vδ1 or Vδ2 cells) population express transgenes, e.g., IL-15Rβ, CAR or other membrane-bound or soluble proteins. In some embodiments, 3%-95% (e.g., 5%-95%, 10%-95%, 20%-95%, 25%-95%, or 50%-95%) of the engineered γδT cells (e.g., Vδ1 or Vδ2 cells) population express transgenes, e.g., IL-15Rβ, CAR or other membrane-bound or soluble proteins. In some embodiments, 3%-90% (e.g., 5%-90%, 10%-90%, 20%-90%, 25%-90%, or 50%-90%) of a population of engineered γδT cells (e.g., Vδ1 or Vδ2 cells) express a transgene, e.g., IL-15Rβ, CAR, or other membrane-bound or soluble proteins.

[0275] VII. Treatment Methods

[0276] Some aspects of the present disclosure relate to a method of treating a patient in need thereof, the method comprising administering to a subject an engineered γδT cell disclosed herein. In some aspects, the subject has cancer. Typically, cancer cells grow and / or live longer than, and out of coordination with, the normal cells and tissues surrounding them. Cancer can be benign, precancerous, or malignant. Cancer occurs in a variety of cells and tissues, including the oral cavity (e.g., mouth, tongue, pharynx, etc.), digestive system (e.g., esophagus, stomach, small intestine, colon, rectum, liver, bile duct, gallbladder, pancreas, etc.), respiratory system (e.g., larynx, lungs, bronchi, etc.), bones, joints, skin (e.g., basal cell, squamous cell, meningioma, etc.), breast, reproductive system (e.g., uterus, ovaries, prostate, testicles, etc.), urinary system (e.g., bladder, kidneys, ureters, etc.), eyes, nervous system (e.g., brain, etc.), endocrine system (e.g., thyroid, etc.), and hematopoietic system (e.g., lymphoma, myeloma, leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, etc.).

[0277] In some aspects, the disease or disorder comprises cancer, e.g., the subject has cancer. In some aspects, cancer comprises bone cancer, pancreatic cancer, skin cancer, head or neck cancer, skin or intraocular malignant melanoma, lung cancer (e.g., non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)), uterine cancer, ovarian cancer, rectal cancer, anal region cancer, stomach cancer, testicular cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease (Hodgkin's Disease), non-Hodgkin's lymphoma, esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, chronic or acute leukemia, acute myeloid leukemia (AML) (e.g., relapsed or refractory AML), chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia (ALL), chronic myeloid leukemia, solid tumors in children, lymphocytic lymphoma, bladder cancer, kidney cancer or ureter cancer, renal pelvis cancer, central nervous system (CNS) tumors, primary CNS lymphoma, tumor angiogenesis, spinal cord axis tumors, brain stem gliomas, pituitary adenomas, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphoma, environmentally induced cancers (including asbestos-induced cancers) or any combination thereof. In some aspects, the cancer is locally advanced. In some aspects, the cancer is metastatic. In some aspects, the cancer is refractory. In some aspects, the cancer is recurrent. In some aspects, the cancer is refractory or recurrent after one or more previous anticancer therapies. In some aspects, the one or more previous anticancer therapies include standard of care therapy.

[0278] In some aspects, the compositions disclosed herein are administered in combination with additional anticancer therapies. In some aspects, additional anticancer therapies include chemotherapy, immunotherapy, radiotherapy, surgery, or any combination thereof. In some aspects, additional anticancer therapies include chemotherapy. In some aspects, additional anticancer therapies include immune checkpoint inhibitors. In some aspects, additional anticancer therapies include PD-1 antagonists, PD-L1 antagonists, CTLA-4 antagonists, LAG-3 antagonists, GITR antagonists, or any combination thereof. In some aspects, anticancer therapies include antibodies or antigen-binding portions thereof that specifically bind and inhibit PD-1 (e.g., pembrolizumab or nivolumab). In some aspects, anticancer therapies include antibodies or antigen-binding portions thereof that specifically bind and inhibit PD-L1 (e.g., atezolizumab, avelumab, or durvalumab).

[0279] In some aspects, the method also includes pre-treating the subject before administering the immune cell colony. In some aspects, chemotherapy is administered to the subject before administering the immune cell colony. In some aspects, immunodepletion chemotherapy is administered to the subject before administering the immune cell colony. In some aspects, immunodepletion chemotherapy comprises cyclophosphamide, fludarabine, or both.

[0280] In some aspects, the method comprises administering to a subject (i) an engineered innate lymphoid cell disclosed herein and (ii) a cytokine. In some aspects, the cytokine comprises IL-2, an analog thereof, a variant thereof, or a fragment thereof.

[0281] In some aspects, the cells of the present disclosure are expressed at a rate of at least about 1 x 10 6 cells, at least about 2x10 6 cells, at least about 3x10 6 cells, at least about 4 x 10 6 cells, at least about 5 x 10 6 cells, 1x 10 7 cells, at least about 2 x 10 7 cells, at least about 3x 10 7 cells, at least about 4 x 10 7 cells, at least about 5 x 10 7 cells, 1x 10 8 cells, at least about 2 x 10 8 cells, at least about 3x 10 8 cells, at least about 4 x 10 8 cells, at least about 5 x 10 8cells, 1x 10 9 cells, at least about 2 x 10 9 cells, at least about 3 x 10 9 cells, at least about 4 x 10 9 cells or at least about 5 x 10 9 A dose of 10 cells is administered to a subject.

[0282] Unless otherwise indicated, the practice of the present disclosure will employ conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are fully explained in the literature. See, e.g., Sambrook et al., eds. (1989) Molecular Cloning A Laboratory Manual (2nd ed.; Cold Spring Harbor Laboratory Press); Sambrook et al., eds. (1992) Molecular Cloning: A Laboratory Manual, (Cold Springs Harbor Laboratory, NY); D. N. Glover, ed. (1985) DNA Cloning, Vols. I and II; Gait, ed. (1984) Oligonucleotide Synthesis; Mullis et al., U.S. Pat. No. 4,683,195; Hames and Higgins, eds. (1984) Nucleic Acid Hybridization; Hames and Higgins, eds. (1984) Transcription And Translation; Freshney (1987) Culture Of Animal Cells (Alan R. Liss, Inc.); Immobilized Cells And Enzymes (IRL Press) (1986); Perbal (1984) A Practical Guide To Molecular Cloning; the treatise, Methods In Enzymology (Academic Press, Inc., NY); Miller and Calos (1987) Gene Transfer Vectors For Mammalian Cells, (Cold Spring Harbor Laboratory); Wu et al. (1987) Methods In Enzymology, Volumes 154 and 155; Mayer and Walker (1987) Immunochemical Methods In Cell And Molecular Biology (Academic Press, London); Weir and Blackwell (1986) Handbook Of Experimental Immunology, Volumes I-IV; Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1986)); Crooke, Antisense drug Technology: Principles, Strategies and Applications, 2nd Edition CRC Press (2007) and Ausubel et al. (1989) Current Protocols in Molecular Biology (John Wiley and Sons, Baltimore, Md.). .

[0283] All references cited above and all references cited herein are incorporated by reference in their entirety.

[0284] The following examples are offered by way of illustration and not limitation.

[0285] Example

[0286] Materials and methods

[0287] Vδ1 T cell isolation and expansion

[0288] Vδ1γδT cell enrichment product (GDX012) was produced using a modified protocol based on Almeida et al. (2016) Clin. Cancer Res. 22: 5795–804. Briefly, peripheral blood mononuclear cells depleted of αβT cells were expanded in G-Rex (Wilson Wolf) culture flasks using serum-free medium (CTS OpTmizer, Thermo Fisher) supplemented with 2.5% autologous plasma and Glutamax (Thermo Fisher). The isolated cells were grown in the presence of recombinant IL-4 [rIL4] (100 ng / mL), recombinant interferon-γ [rIFNγ] (70 ng / mL), recombinant IL-21 [rIL21] (7 ng / mL), recombinant IL-1β [rIL1β] (15 ng / mL) and soluble OKT-3 monoclonal antibody (42 ng / mL). Cells were incubated in a humidified incubator at 37°C and 5% CO2. Expanded cells were regularly fed with fresh medium containing recombinant IL-15 [rIL15] ('high': day 5: 21 ng / mL and day 7: 100 ng / mL; or 'low': day 5: 2.1 ng / mL and day 7: 10 ng / mL).

[0289] Retroviral transduction

[0290] The amplified γδT cells were transduced with retroviral vectors in a cell expansion bag (PermaLife bag, OriGen Biomedical) coated with Retronectin (20 mg / mL) at a defined multiplicity of infection (MOI). MOI refers to the number of infectious particles added to each cell during transduction (measured by flow cytometry). The viral vector was diluted in CTS OpTmizer medium. The transduction efficiency was determined by flow cytometry at regular intervals three days after transduction.

[0291] Retroviral vector production and titration

[0292] Gammaretroviral vectors were produced by transient transfection of human fetal kidney (HEK) cells with murine leukemia virus genomic plasmids. Vectors were harvested 96 hours after transfection, filtered through a 0.45 μm pore size polyethersulfone (PES) filter and concentrated using hollow fiber filtration.

[0293] Vector titers were determined by transducing the SupT1 (acute lymphoblastic leukemia) cell line with serial dilutions of concentrated vector material in the presence of Retronectin (20 μg / mL). Transduction efficiency was determined three days after transduction using a BD FACSLyric flow cytometer. Infectious titers (TU / mL) were calculated using the following formula: TU / mL = ((number of transduced cells) x vector dilution x (% transduction efficiency / 100)) / vector volume (mL).

[0294] Flow cytometry

[0295] Immunophenotyping was performed using a BD FACS Lyric flow cytometer. Cells were analyzed for expression of surface markers using the antibodies listed in Table 5 below:

[0296] Table 5. Cell surface markers Fluorophore Markers source BV421 CD27 BioLegend BV510 L / DAQUA ThermoFisherScientific BV605 TCRαβ BioLegend FITC CAR AcroBiosystems PE NKG2D BioLegend PE-Cy7 CD56 BioLegend APC TCRγδ BioLegend APC-Cy7 Vδ1 MiltenyiBioTec BV421 DNAM-1 BioLegend BV605 PD-1 BioLegend PE NKp30 BioLegend PE-Cy7 TIGIT BioLegend PE IL-15Rα BioLegend PE-Cy7 IL-15Rβ BeckmanCoulter APC IL-15 R&D Systems APC Common gamma chain BioLegend

[0297] Cytotoxicity assessment

[0298] Amplified cells and suspended tumor targets (e.g., NALM-6) expressing firefly luciferase are co-cultured with various effectors and target ratios. Target cells in the absence of effectors serve as controls (Ctrl). Maximum dissolution is determined using target cells treated with Staurosporine. After 20 hours, ONE-GloTM luciferase assay system kit (Promega) or SYTOXA ADvanced dead cell staining kit (ThermoFisher) are used to assess the quantification of target activity. Luminescence is measured on Biotek Synergy H4 plate reader (luciferase system), and SYTOXA ADvanced dead cell staining is measured by flow cytometry on MACSQuant (Miltenyi).

[0299] IL-15 ELISA

[0300] IL-15 production was measured using a commercially available human IL-15 Quantikine ELISA kit (Bio-Techne) according to the manufacturer's instructions. IL-15 production was measured 72 hours after incubation.

[0301] Repeated antigen stimulation assay

[0302] CD19 Model

[0303] In order to evaluate the expansion of CAR-modified Vδ1T cells and CAR-T cell enrichment, repeated antigen stimulation (RAS) assays were performed. In the presence (10ng / mL or 70pg / mL) or in the absence of IL-15, the freshly thawed drug product was resuspended in RPMI10 medium (RPMI, 10% FBS). The target tumor cell line was counted using an automatic cell counter (NC250), and the concentration was adjusted to 1E+06 cells per milliliter. 2X cytokine concentrations were added to the target cells, and 100 μL (1E+05 cells) were transferred to each well of a 96-well round-bottom plate. The concentration of effector cells was adjusted to 2E+06 live cells per milliliter, and 100 μL (2E+05 cells) were spread in wells containing target cells. Depending on the number of effector cells, replicate wells were plated for each condition. The co-culture was maintained at 37 ° C, 5% CO2 for 14 days. Duplicate wells were pooled, counted, and phenotyped using a BD FACSLyric flow cytometer on days 4, 7, and 10. The remaining cells were then centrifuged and resuspended in fresh medium at a density of 2E+06 viable cells / mL and layered on another round of target cells, as prepared on day 0.

[0304] A549-Meso Model

[0305] Drug product was thawed and co-cultured with A549-MLSN-fluc-gfp cells in 24-well plates (300,000 effectors to 150,000 targets) at an E:T ratio of 2:1 in Incucyte in the presence or absence of 1 ng / mL IL-15 to track GFP fluorescence over time as a surrogate for tumor cell lysis. On days 2 and 9 of culture, cells were fed with fresh medium plus or minus 1 ng / mL IL-15, and 50% of the well volume was replaced by careful aspiration after centrifugation. On days 4 and 11 of culture, cells were fed with fresh medium containing targets (150,000 per well) plus or minus 1 ng / mL IL-15, and 50% of the well volume was replaced by careful aspiration after centrifugation. On day 7, all wells were harvested, counted, and re-seeded at an E:T of 2:1 as on day 0. Tumor confluence was measured by tracking GFP fluorescence over time.

[0306] Survival assay

[0307] The frozen drug product was thawed and the viable cell concentration was adjusted to 2E+06 cells per milliliter in RPMI10. 2E+05 cells were inoculated per well for multiple wells. On days 0, 3, 7, 10, and 14, the replicate wells were stained by adding SytoxAADvanced dye directly to the culture medium in the dark at room temperature for 10 minutes. 40 microliters of samples were analyzed on a MACSQuant flow cytometer without further processing for cell quantification and viability assessment. To determine the viability of CAR+Vδ1+T cells, the replicate plates were stained with CAR, Vδ1, and pan-γδT cell markers and analyzed by flow cytometry.

[0308] In vivo efficacy models

[0309] CD19 Model

[0310] 8-10 week old NSG and IL-15 expressing transgenic NOG-IL-15 mice were implanted with 5x105 NALM6-fluc-GFP cells via intravenous (IV) injection. On day 7, mice were injected with vehicle (n=5 NSG mice, Cryostor CS5, Group 1) or one of the three drug products muCAR19.b, muCAR19.ab or muCAR19.a.15.b under the following 3 experimental conditions: NSG mice + 1 μg IL-15, administered daily via IP injection (N=9, Groups 2-4), NSG mice, not given IL-15 (N=4-9, Groups 5-7) and NOG-hIL15 mice, not given IL-15 (N=6, Groups 8-10). Fig.13 Grouping table included. After intraperitoneal (IP) injection of 150 mg / kg d-luciferin, mice were imaged using an IVIS camera twice a week. On the 10th day (3 days after drug product administration), N=4 mice were selected from groups 2, 3, 4, and 7, and bone marrow aspirates were harvested from femurs, spleens, and peripheral blood (collected in lithium heparin tubes). Samples were processed into single cell suspensions and stained for flow cytometry analysis. Samples were analyzed using a BD FACSLyric flow cytometer.

[0311] A549-Meso Model

[0312] 6-8 week old NSG mice were implanted with 1x106 A549-MSLN-fluc-GFP cells by intravenous (IV) injection. On the 19th day after implantation, mice were injected with vehicle (n=7, CryostorCS5, Group 1), P4γδCART cells, 10 million total cells per mouse (n=7, Group 2), P4α.15.βγδCART cells, 10 million total cells per mouse (n=7, Group 3) or P4.βγδCART cells, 10 million total cells per mouse (n=7, Group 4). After intraperitoneal (IP) injection of 150mg / kg d-fluorescein, mice were imaged using IVIS camera, twice a week. Mice in Group 4 were given 1μg IL-15 via IP injection every day. On day 19 after drug product administration, all mice were selected and bone marrow aspirates were harvested from the femur, spleen, and peripheral blood (collected in lithium heparin tubes).

[0313] Example 1: Schematic overview of 'conventional' and novel IL-15 armored constructs

[0314] Currently used armored strategies utilize secretory (sIL-15) constructs or membrane-tethered IL-15 (mbIL-15) constructs. These strategies have been shown to enhance the survival and proliferation of αβT cells (Hurton LV. et al., PNAS, 113, E7788–E7797, (2016)), NK cells (Liu et al., Leukemia 32, 520–531 (2018)) and iNK-T (Xu et al., Clin Cancer Res., 25, 7126-7138 (2019)) cells.

[0315] As part of the present invention, a panel of novel constructs were designed and evaluated in Vδ1γδ T cells ( Figure 1 A). A polycistronic gammaretroviral vector was generated in which the chimeric antigen receptor (CAR) coding sequence was fused in frame to individual IL-15 receptor chain components encoding wild-type or IL-15 fusion (tethered) chain variants. Figure 1 B and Figure 1 C shows a schematic diagram of the gamma-retroviral vector used to co-express CAR and armor moiety.

[0316] Example 2: The ‘conventional’ IL-15 armored strategy is suboptimal for the expansion of blood-derived Vδ1 T cells

[0317] To determine whether the currently used (conventional) IL-15 armor strategy can drive the expansion of engineered Vδ1T cells, isolated Vδ1T cells were transduced with non-armored secretory IL-15 (sIL-15) or membrane-bound IL-15 (mbIL-15) CAR constructs. After transduction, cells were expanded in the presence of IL-15 as described in the methods section ('high' IL-15 feeding). CAR expression was monitored regularly via flow cytometry during the expansion phase, and the total number of cells was enumerated via automated cell counting. The absolute number of live CAR+Vδ1+ cells (total number of live cells multiplied by the percentage of CAR+Vδ1+T) was plotted against the number of expansion days to determine the effect of armor on the fold expansion of Vδ1T cells ( Figure 2 A).

[0318] Figure 2 A shows that in the presence of IL-15, unarmored CAR-modified Vδ1 T cells are continuously enriched during the culture period. In contrast, conventional IL-15 armored Vδ1 T cells show limited proliferation during the expansion procedure, suggesting that armored cells are desensitized to exogenous IL-15. Drug product analysis revealed that armored cells do express mbIL-15 (muCAR19.mbIL-15) on their surface and secrete IL-15 (muCAR19.sIL-15). Figure 2 B shows the surface expression of IL-15 and IL-15Rα chain on mbIL-15 armored CAR+Vδ1+ T cells. Figure 2 C shows the functionality of sIL-15 armored CAR+Vδ1+T measured by overnight IL-15 ELISA.

[0319] Example 3: ‘Conventional’ IL-15 armoring strategy provides limited survival and proliferation signals to blood-derived Vδ1 T cells

[0320] Next, the conventional armoring strategy was tested to improve the cytotoxicity, survival and proliferation of armored CAR-modified Vδ1 T cells. To this end, overnight cytotoxicity assays, survival assays and repeated antigen stimulation assays (using NALM-6 target cells) were performed using freshly thawed drug products.

[0321] In an overnight cytotoxicity assay, conventional armored CAR+Vδ1+ T cells exhibited comparable lytic activity to non-armored CAR-modified Vδ1 T cells ( Figure 3 A). Figure 3 B shows that unarmored and sIL-15 armored cells fail to survive in the absence of exogenous IL- 15. In contrast, armoring of cells with mbIL-15 resulted in a slight improvement in cell survival as assessed by flow cytometry (viable lymphocyte population).

[0322] Surprisingly, in the repeated antigen stimulation assay, none of the conventional IL-15 armored CAR+Vδ1+ T cells were enriched in the presence of IL-15 ( Figure 3 C). It is noteworthy that the same phenomenon was observed in the absence of IL-15 in the RAS assay (data not shown). This is in stark contrast to unarmored cells, which continuously enriched CAR-modified Vδ1T cells under repeated NALM-6 attacks. Overall, the results show that cells armored with conventional IL-15 armored constructs retain killing ability but lose the ability to amplify and enrich when target cells are engaged. The data also show that conventional strategies (sIL-15) do not or only slightly increase (mbIL-15) Vδ1T cell survival.

[0323] Example 4: Reducing IL-15 concentration during the expansion step does not rescue the proliferation of mbIL-15 armored CAR-modified Vδ1 T cells

[0324] To further examine the impact of the mbIL-15 armoring strategy, unarmored and mbIL-15 armored CAR-transduced Vδ1 T cells were expanded in the presence of high and low IL-15 concentrations, and the fold expansion of the cells was monitored ( Figure 4 ). Consistent with previous results, both high and low IL-15 concentrations supported the expansion of unarmored Vδ1+ T cells. In contrast, mbIL-15-armored CAR+Vδ1+ T cells could not be enriched even at a 10-fold lower IL-15 dose. Overall, the results suggest that mbIL-15 armored cells lose the ability to respond to exogenous IL-15 and that the proliferation of armored cells cannot be rescued by reducing the IL-15 dose during the expansion process.

[0325] Example 5: IL-15Rβ chain transfer restores proliferation of mbIL-15 armored CAR-modified Vδ1 T cells

[0326] To simplify the context, IL-2Rβ will be referred to as IL-15Rβ throughout the document.

[0327] Since mbIL-15 armored cells are activated in the presence of exogenous IL-15 ( Figure 2 A and Figure 4 ) and during repeated antigenic challenge ( Figure 3 C) all exhibited negligible proliferation, so we hypothesized whether overexpression of the common β chain could restore proliferation of transduced cells.

[0328] First, we tested whether the expanded blood-derived Vδ1 T cells expressed any detectable levels of the IL-15Rβ chain on their surface. High-throughput flow cytometric analysis (LEGENDScreen) revealed that unmodified Vδ1 T cells did not express either IL-15Rα or IL-15Rβ chains. Figure 5 ). In contrast, Vδ1 T cells exhibited high-level and uniform expression of the common γ chain.

[0329] Having shown that Vδ1 T cells express negligible amounts of the IL-15Rβ chain on their surface, we further determined the effect of co-expression of IL-15Rβ and either IL-15-tethered or wild-type IL-15Rα chains ( Figure 1 B and Figure 1 C). To this end, the expanded Vδ1T cells were transduced with CAR constructs armored with membrane-tethered IL-15 (mbIL-15 = α.IL-15), membrane-tethered IL-15 and IL-15Rβ (α.IL-15.β), and IL-15Rα and β (IL-15.α.β) chains. The transduced cells were then expanded in the presence of exogenous IL-15, and the fold expansion was continuously monitored during the expansion process. Figure 6 A shows the fold expansion of armored CAR+Vδ1+T cells over time. The data revealed that transduction of cells with IL-15Rβ chain restored the proliferation of CAR+Vδ1+T cells armored with (IL-15 tethered and wild-type) IL-15Rα chain. Surprisingly, in the presence of exogenous IL-15, IL-15Rα and β chain co-expressing cells exhibited significantly higher fold expansion than tethered IL-15 and β chain expressing cells. Importantly, tethered IL-15 and β chain co-expressing cells showed comparable fold expansion to unarmored cells ( Figure 6 A, triangles and circles. This phenomenon was consistently observed at two different IL-15 doses ( Figure 6 B), clearly demonstrates that co-expression of the IL-15Rβ chain rescues the expansion of mbIL-15 engineered cells in response to exogenous IL15.

[0330] Example 6: CAR-modified Vδ1 T cells co-expressing IL-15Rα and β chains are cytotoxic and proliferate during repeated antigen challenge

[0331] After determining that co-expression of IL-15Rα and β chains could restore exogenous IL-15-induced proliferation of CAR-modified Vδ1+ T cells, the functionality of the modified cells was next investigated. Figure 7 A shows representative short-term (overnight) cytotoxicity results from two donors. Armoring of Vδ1 T cells with additional IL-15R chain components did not have any adverse effects on the cytotoxic activity of the cells. Importantly, β chain co-expressing cells exhibited cytotoxicity comparable to mbIL-15 armored cells.

[0332] The next step was to determine whether CAR-transduced, IL-15Rα and β chain co-expressing Vδ1 T cells could be enriched after repeated antigen stimulation with CD19+NALM-6 acute lymphoblastic leukemia cells. To this end, freshly thawed armored drug products were co-cultured with NALM-6 target cells in the presence (10 ng / mL) or absence of exogenous IL-15 as described in the methods section. Effector cells were restimulated with fresh target cells every 3-4 days. The fold expansion and enrichment of CAR+Vδ1+ effectors, as well as target cell clearance, were monitored during the assay.

[0333] As mentioned previously ( Figure 3 C), conventional mbIL-15 armored CAR+Vδ1+ T cells failed to proliferate under any conditions examined ( Figure 7 B and Figure 7 C, left panel, open squares). This is reflected in the rapid decline in the number of CAR+Vδ1+ T cells. Compared with mbIL-15 armored cells, the number of cells co-expressing IL-15Rα and β chains declined even more rapidly in the absence of exogenous IL-15 ( Figure 7 B, left panel, black squares). In contrast, in the absence of IL-15, cells co-expressing tethered IL-15 (α.IL-15) and the β chain were enriched during the assay ( Figure 7 B, left and middle panels, triangles). These results suggest that, in the absence of exogenous IL-15, tethered IL-15 acts as a proliferation and survival-inducing signal for IL-15Rα and β co-expressing cells. Enumeration of the number of target cells remaining during the assay revealed that only tethered IL-15 and IL-15Rβ chain co-expressing cells were able to show long-term tumor control ( Figure 7 B, right, triangle).

[0334] Surprisingly, in the presence of supraphysiological levels of IL-15 (10 ng / mL), IL-15Rα and β co-expressing cells exhibited enhanced expansion compared to tethered IL-15 and β chain co-expressing cells ( Figure 7 C, left panel). These data suggest that the availability of exogenous IL-15 may fine-tune the activity of cells co-expressing tethered IL-15 and the β chain. Overall, co-expression of the IL-15R β chain did not adversely affect the cytotoxicity of the cells, and most importantly, in the presence of tethered IL-15, longer periods of tumor control were achieved than in the absence of exogenous IL-15.

[0335] Example 7: Vδ1 T cells co-expressing IL-15Rα and β chain exhibit enhanced expansion in the presence of exogenous IL-15 compared to cells expressing β chain alone

[0336] Having demonstrated that the presence of the IL-15Rβ chain is required to restore proliferation of transduced Vδ1 T cells, the next goal was to determine whether armoring cells with the β chain alone could drive cell proliferation. To investigate the function of the β chain, Vδ1 T cells were transduced with CAR constructs armored with the IL15Rβ chain alone or in combination with IL-15Rα or IL-15 tethered IL-15Rα chains. Figure 8 A shows the percentage of CAR+Vδ1+T cell populations two days after transduction (N=2 representative donors). As expected, CAR gene transfer efficiency is negatively correlated with the size of the viral vector construct. At a fixed multiplicity of infection, the smaller (3150bp) IL-15Rβ armored construct always produces a higher CAR transduction efficiency than the larger (IL15Rα.β or IL-15Rα.15.β) size (3993bp and 4413bp, respectively) construct. Figure 8 B shows the expression of individual chain components and IL-15 expression within a population of CAR-transduced Vδ1 T cells. Importantly, these representative flow charts show that CAR-modified Vδ1 T cells express equimolar levels of CAR and armor components on their surface.

[0337] After transduction with the above IL-15Rβ chain co-expression construct, the number of CAR+Vδ1+ T cells was monitored during the cell expansion procedure. Consistent with previous experiments ( Figure 6 A), IL-15Rα and β chain co-expressing cells showed the highest level of expansion, followed by IL-15Rβ chain (alone) armored cells ( Fig. 9 A) To test whether the expansion of cells expressing the β chain was dependent on exogenous IL-15 availability, the expansion procedure was repeated in the presence of high and low IL-15 concentrations. Fig. 9 B shows the fold expansion of CAR+Vδ1+T cells armored with three different β chain co-expression constructs. The data indicate that IL-15Rα and β chain co-expressing cells become more sensitive to exogenous IL-15 than β chain alone or tethered IL-15 and β chain co-expressing cells.

[0338] Example 8: Armored cells are selectively enriched during the culture period and show improved DNAM-1 and NKp30 expression

[0339] After amplification, the transduced drug substance was harvested, formulated, and cryopreserved. Transduction efficiency was determined after thawing ( Fig.10 A). Flow cytometry analysis did not reveal any significant differences in CAR transduction efficiency between different armored conditions. In general, expansion of cells using low-dose IL-15 resulted in a slight increase in the proportion of transduced cells.

[0340] Next, the surface expression of CAR and individual armor molecules was evaluated. Fig.10 B shows that freshly thawed cells retain equimolar surface expression of CAR and IL-15R armor molecules.

[0341] Comparison of CAR transduction efficiency 3 days after transduction with that at the end of the expansion process revealed that armored cells were selectively enriched during the culture period ( Fig.10 C). Notably, cells co-expressing the α and β chains showed the highest level of enrichment between days 7 and 14 of the culture period. This effect was more prominent under low IL-15 feeder culture conditions. In contrast, unarmored CAR-modified cells were not enriched during the expansion procedure. Expanded cells exhibited steady-state CAR expression during the culture process. This further supports the finding that IL-15Rα and β chain armored cells were selectively enriched during the culture period.

[0342] Next, we proceeded to determine the cellular composition of the cells. FACS analysis did not reveal any significant qualitative or quantitative differences in the pan-γδ, Vδ1γδ T cell and non-γδ T cell populations (data not shown).

[0343] Phenotypic characterization of armored CAR-transduced and non-transduced Vδ1 T cell populations revealed subtle differences in the expression of NKG2D, NKp30, DNAM-1, PD-1, and TIGIT ( Fig.10 D).

[0344] Compared with the untransduced Vδ1T cell population, the proportion of cells expressing the natural cytotoxic receptor NKp30 doubled in the CAR-expressing population of all armored cells except for membrane-tethered IL-15 and β-chain co-expressing cells. Similarly, an increase in the frequency of activated DNAM-1 receptor-expressing cells was observed in the armored cell population expressing CAR. In contrast, the opposite trend was observed in the case of Vδ1T cells expressing NKG2D: the proportion of Vδ1T cells expressing NKG2D in the CAR-expressing cell fraction was slightly decreased compared with the untransduced fraction. These data suggest that β-chain co-expression (in the case of wild-type and IL-15α chains) may give cells a more cytotoxic phenotype.

[0345] Example 9: Vδ1 T cells modified with novel IL-15 armored constructs show comparable or enhanced efficacy

[0346] The cytotoxic activity of novel β-chain armored CAR-modified Vδ1 T cells was evaluated in an overnight killing assay in the presence and absence of exogenous IL-15. In the case of CD19-targeted CAR, when targeting a tumor target expressing CD19 (NALM-6), in the absence of IL-15 ( Fig.11A), armored cells did not show any significant differences in potency; however, there was a trend toward increased cytotoxic activity in IL-15Rα and β co-expressing cells in the presence of IL-15 ( Fig.11 B).

[0347] In contrast, in the absence of exogenous IL-15, anti-CD123 ( Fig.11 D) or anti-mesothelin targeted ( Fig.11 E) CAR Vδ1 T cells exhibit enhanced cytotoxicity compared to unarmored cells. To further test whether armoring has an effect on the potency of Vδ1 T cells in the absence of CAR engagement, the short-term cytotoxicity of unarmored and armored CD19-targeting CAR-modified Vδ1 T cells was compared with CD19-negative (but Vδ1 T cell-sensitive) targets (MV4-11 or MOLM-13) ( Fig.11 C) Comparison. As expected, the cytolytic activity of cells co-expressing tethered IL-15 and IL-15Rβ was significantly enhanced.

[0348] Example 10: Tethered IL-15 and IL-15Rβ chain co-expressing CAR-modified Vδ1 T cells survive in the absence of exogenous IL-15

[0349] The next question addressed whether these novel armor strategies could support the survival of armored CAR-modified Vδ1 T cells. In the absence of exogenous cytokine support, freshly thawed drug products (n=2 donors) were plated in 96-well plates at 2E+06 cells per ml. The total number of viable cells and the percentage of CAR+Vδ1+T cells were regularly monitored for two weeks. Fig.12 A and Fig.12 C shows that only tethered IL-15 and IL-15Rβ co-expressing cells survive and proliferate. In the absence of exogenous IL-15 support, IL-15Rβ alone and IL15Rα and β co-expressing cells die rapidly. This is reflected in the rapid decline in the total number of CAR+Vδ1+T cells and the percentage of live lymphocytes during the assay ( Fig.12 A and Fig.12 D). Fig.12 C shows the percentage of CAR+Vδ1+T cells over time. In this assay, only cells co-expressing tethered IL-15 and IL-15Rβ chain were enriched. Flow cytometric analysis revealed that this was a consequence of the rapid loss of the non-transduced Vδ1T cell population, because in the absence of exogenous IL-15, non-transduced cells could not survive ( Fig.12 B). Interestingly, cells co-expressing tethered IL-15 and IL-15Rβ chain appeared to be able to support survival of non-transduced cells from day 3 to the end of the assay ( Fig.12 B).

[0350] To demonstrate that the armored effect is independent of the chosen CAR molecule, previous experiments were repeated using armored Vδ1 T cells modified with a CAR targeting mesothelin ( Fig.15 A). Indeed, mesothelin-targeting CAR cells co-expressing tethered IL-15 and IL-15Rβ survived 14 days after cryopreservation, whereas unarmored cells declined rapidly. Importantly, the survival benefit of armored cells remained constant regardless of the type of mesothelin-targeting conjugate used in the CAR construct (YP218 or P4). Fig.15 A) These results show that the functional properties conferred by co-expression of tethered IL-15 and IL-15Rβ chain are independent of the CAR and / or binder used.

[0351] Overall, the results indicate that co-expression of IL-15Rα and β is necessary but not sufficient to support the survival of CAR-modified Vδ1 T cells in the absence of exogenous IL-15. To achieve long-term survival of cells, IL-15 must be tethered to the IL-15Rα chain.

[0352] Example 11: CAR-modified Vδ1 T cells co-expressing tethered IL-15 and IL-15Rβ chain are enriched after repeated antigen stimulation in the presence of physiological levels of IL-15

[0353] Next, we evaluated whether the transfer of the IL-15Rβ chain alone or in combination with the IL-15Rα chain was sufficient to drive the selective enrichment of CAR-modified Vδ1T cells during repeated tumor challenges. In addition, we also investigated whether physiological (pg / mL) IL-15 concentrations could support the growth of armored cells. To this end, repeated antigen stimulation assays were performed in the presence of two IL-15 concentrations: supraphysiological (10 ng / mL) and physiological (70 pg / mL).

[0354] Fig.13 A-13C (left panel) shows that at supraphysiological IL-15 concentrations, the armored constructs were able to support the proliferation and enrichment of CAR-modified Vδ1 T cells, with IL-15Rα.β and IL15-Rβ being the most effective. Consistent with this, armored CAR-modified cells were able to eliminate repeated challenges of NALM-6 cells during the assay ( Fig.11 C).

[0355] This is in stark contrast to the results using physiological (pg / mL) IL-15 concentrations ( Fig.13 D-13F, right). In the presence of low IL-15 concentrations, only cells co-expressing membrane-tethered IL-15 and IL-15R.β chain were able to continue to proliferate and enrich ( Fig.11 D and Fig.11E) Nevertheless, in the presence of physiological IL-15 concentrations, these cells exhibited an overall lower fold expansion than that observed in the presence of supraphysiological IL-15 concentrations.

[0356] After three rounds of tumor challenge, the number of armored Vδ1 T cells expressing the β chain alone as well as the α and β chains declined rapidly. This coincided with the loss of tumor control and outgrowth of NALM-6 target cells. Surprisingly, this was not the case for cells co-expressing membrane-bound IL-15 and IL-15Rβ chains, which maintained the ability to clear NALM-6 cells upon repeated challenge.

[0357] To demonstrate that the armoring effect was independent of the chosen CAR molecule, the above experiments were repeated with unarmored and tethered IL-15 and IL-15Rβ chain-armored Vδ1 T cells expressing the anti-mesothelin CAR ( Fig.15 B-15E). Fig.15 B shows that in the absence of exogenous IL-15, tethered IL-15 and IL-15Rβ chain armored Meso-CART cells are able to control repeated attacks of A549 cells expressing mesothelin. Importantly, the above findings were not affected by the choice of mesothelin conjugate (YP218 or P4). In addition, the enhanced tumor control exhibited by tethered IL-15 and IL-15Rβ chain armored CAR T cells was not related to cell proliferation. Instead, the proliferation potential appears to be driven by the CAR molecule itself and is specific to the conjugate used. Proliferation was observed when the YP218 conjugate was used but not when the P4 conjugate was used ( Fig.15 C). In the presence of low levels of IL-15 (1 ng / mL), IL-15Rβ chain-armored P4 CAR T cells were also able to provide excellent tumor control during repeated tumor challenge ( Fig.15 D). Enhanced functionality was significantly associated with increased sensitivity to exogenous IL-15 and increased proliferation during repeated tumor challenge ( Fig.15 E).

[0358] These results clearly demonstrate that at physiological IL-15 concentrations, membrane-bound IL-15 and IL-15Rβ chain-expressing cells can proliferate, survive, and exhibit effective tumor control.

[0359] Example 12: In vivo efficacy study of NALM-6 using NSG and NOG-IL15 mice

[0360] To confirm the in vitro findings, the in vivo efficacy of the drug product was evaluated in the NALM6-FLuc systemic tumor model, where tumor burden was tracked twice weekly via non-invasive bioluminescence imaging (BLI) ( Fig.14 A). Each drug product was evaluated under three conditions: NSG mice ( Fig.14 B) NSG mice without exogenous IL-15 ( Fig.14 C) or NOG IL-15 transgenic mice (Taconic, hIL-15NOG (model 13683), Fig.14 D). In the presence of exogenous IL-15, all three constructs provided equivalent tumor control, with all groups showing BLI equivalent to background 6 days after dosing (study day 13) ( Fig.14 B). In transgenic NOG mice, IL-15 concentrations in peripheral blood approached human physiological levels (approximately 50 pg / mL), and all groups again exhibited equivalent tumor control ( Fig.14 D). However, in the absence of exogenous IL-15, while all constructs were able to control tumor growth to some extent, only the muCAR19.α.15.β armored construct was able to reduce tumor burden to below detectable levels 10 days after dosing (study day 17) ( Fig.14 C).

[0361] Satellite mice were also selected 3 days after dosing (study day 10) to assess the relative number of Vδ1+ and CAR+ cells. In the presence of exogenous IL-15, all constructs showed significant differences in total cell number ( Fig.14 E) and the percentage of CAR-expressing cells were comparable to the drug product before injection ( Fig.14 F). In the absence of exogenous IL-15, mice given muCAR19.α.15.β had equal numbers of Vδ1+, CAR+ cells, but there was a loss of CAR-untransduced cells, observed as a loss in the absolute number of CAR- cells, and an increase in the % Vδ1+CAR showing a survival advantage in the armored compartment. In the absence of IL-15, this survival advantage was further enhanced at the end of the study, 13 / 14 days after dosing ( Fig.14 J), in which mice given muCAR19.α.15.β had a more than 100-fold increase in the survival rate of CAR+Vδ1 T cells compared to mice given muCAR19.α.β and muCAR19.β ( Fig.14 L). This increased survival was also associated with the complete absence of detectable residual NALM-6 tumor cells in the bone marrow of mice given muCAR19.α.15.β, whereas muCAR19.α.β and muCAR19.β had an average of hundreds or thousands of residual NALM6 cells (respectively) in bone marrow harvested from the hind femur ( Fig.14 M). In the presence of exogenous IL-15, all three treatment groups showed an increase in CAR+ and CAR-Vδ1 T cells starting from day 3 after administration ( Fig.14 K vs. Fig.14E). The greatest proportion of CAR+ cells at the end of the study was observed in mice given muCAR19.β ( Fig.14 J), while the other groups showed unchanged (muCAR19.α.β) or decreased (muCAR19.α.15.β) relative to CAR ratio. The trend observed in control NALM6 tumors based on whole-body imaging data was not altered by the acquisition of additional time points (10 days vs. 12 days after dosing): NSG mice given 1 μg IL-15 daily ( Fig.14 B contrast Fig.14 G), NSG mice without exogenous IL-15 ( Fig.14 C contrast Fig.14 H) or NOG IL-15 transgenic mice (Taconic, hIL-15NOG (model 13683), Fig.14 D Comparison Fig.14 I).

[0362] Overall, these results demonstrate that in the presence of exogenous or transgenically expressed IL-15, all constructs were potent and able to control disease in the NALM6 model, but in its absence, muCAR19.α.15.β was uniquely able to reduce residual tumor to below detectable levels.

[0363] Example 13: In vivo efficacy study of A549-MSLN using NSG mice

[0364] To confirm the in vitro findings obtained with armored mesothelin targeting CARVδ1 T cells, the in vivo efficacy of the drug product was evaluated in the disseminated A549-Meso-FLuc tumor model. 6-8 week old NSG mice were implanted with 1x10 6 A549-MSLN-fluc-GFP cells. On day 19 after implantation, mice were injected with vehicle (n=7, CryostorCS5, Group 1), P4 unarmored γδCAR T cells (10 million total cells per mouse) (n=7, Group 2), P4α.15.βγδCART cells (10 million total cells per mouse) (n=7, Group 3) or P4βγδCART cells (10 million total cells per mouse) (n=7, Group 4). Tumor burden was tracked twice a week by non-invasive bioluminescence imaging (BLI) ( Fig.16 A). Fig.16B shows that in the absence of exogenous IL-15, α.15.β armored Vδ1P4 CART cells exhibited better tumor control than unarmored Vδ1P4 CART cells, with P4α.15.β treated mice having a BLI signal that was 10 times lower than that of mice given unarmored cells on average at the end of the study (day 19 after dosing). Consistent with in vitro experiments, in the presence of IL-15, β armored γδCART cells exhibited initial faster tumor elimination kinetics, but overall tumor control was comparable to the α.15.β armored (non-IL-15 supported) γδCART treatment group.

[0365] Other Implementations

[0366] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.

[0367] Although the invention has been described in conjunction with particular embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any changes, uses or adaptations of the invention which generally follow the principles of the invention and which include departures from the present disclosure which come within known or customary practice in the art to which the invention relates and which may apply to the essential features set forth above and which follow within the scope of the claims.

[0368] Other embodiments are within the claims.

Claims

1. A γδT cell, wherein the γδT cell expresses a recombinant IL-15 receptor β subunit (IL-15Rβ). 2 . The γδ T cell according to claim 1 , further expressing a recombinant IL-15 receptor α subunit (IL-15Rα) or a fragment thereof.

3. The γδ T cell of claim 2, wherein the IL-15Rα or a fragment thereof is tethered to IL-15 or a variant thereof. The γδ T cell according to claim 2 or 3, wherein the IL-15Rβ and the IL-15Rα or a fragment thereof are expressed in tandem. The γδ T cell according to claim 4 , further comprising a linker between the IL-15Rβ and the IL-15Rα or a fragment thereof. The γδ T cell of claim 5 , wherein the linker comprises a cleavable peptide. The γδ T cell according to claim 6 , wherein the cleavable peptide is a self-cleaving peptide. The γδ T cell according to claim 7 , wherein the self-cleaving peptide is a 2A peptide.

9. The γδ T cell of claim 8, wherein the 2A peptide is a foot-and-mouth disease virus 18 2A (F2A) peptide, an equine rhinitis A virus 2A (E2A) peptide, a porcine teschovirus-12A (P2A) peptide, or a tricholoma thunbergii virus 2A (T2A) peptide. 10 . The γδ T cell according to claim 9 , wherein the 2A peptide is a P2A peptide.

11. The γδ T cell of any one of claims 1-10, further expressing a chimeric antigen receptor (CAR).

12. The γδ T cell of claim 11, wherein the CAR lacks an intracellular signaling domain.

13. The γδ T cell of any one of claims 1 to 12, wherein the γδ T cell lacks an endogenous gene encoding IL-15. The γδ T cell according to any one of claims 1 to 13, further expressing secretory IL-15 or a variant thereof.

15. A γδ T cell, which expresses recombinant IL-15Rβ and recombinant IL-15 or a variant thereof. The γδ T cell of claim 15 , wherein the IL-15Rβ and the IL-15 or a variant thereof are expressed in tandem. The γδ T cell of claim 16 , further comprising a linker between the IL-15Rβ and the IL-15 or a variant thereof. The γδ T cell of claim 17 , wherein the linker comprises a cleavable peptide. The γδ T cell according to claim 18 , wherein the cleavable peptide is a self-cleaving peptide.

20. The γδ T cell of claim 19, wherein the self-cleaving peptide is a 2A peptide. The γδ T cell according to claim 20 , wherein the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide or a T2A peptide. The γδ T cell according to claim 21 , wherein the 2A peptide is a P2A peptide.

23. The γδ T cell of any one of claims 15 to 22, further expressing recombinant IL-15Rα or a fragment thereof. The γδ T cell of claim 23 , wherein the fragment of IL-15Rα comprises a soluble fragment. The γδ T cell of claim 24 , wherein the soluble fragment comprises a sushi domain.

26. The γδ T cell of claim 25, wherein the sushi domain is attached to an Fc domain.

27. The γδ T cell of any one of claims 23-26, wherein the IL-15Rα or a fragment thereof is tethered to the IL-15 or a variant thereof.

28. The γδ T cell of any one of claims 23-27, wherein the IL-15Rβ and the IL-15Rα or a fragment thereof are expressed in tandem.

29. The γδ T cell of claim 28, further comprising a second linker between the IL-15Rβ and the IL-15Rα or a fragment thereof.

30. The γδ T cell of claim 29, wherein the second linker comprises a cleavable peptide. The γδ T cell of claim 30 , wherein the cleavable peptide is a self-cleaving peptide. The γδ T cell of claim 31 , wherein the self-cleaving peptide is a 2A peptide. The γδ T cell of claim 32 , wherein the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide, or a T2A peptide. The γδ T cell of claim 33 , wherein the 2A peptide is a P2A peptide.

35. The γδ T cell of any one of claims 23-34, wherein the IL-15Rβ, the IL-15 or a variant thereof, and the recombinant IL-15Rα or a fragment thereof are expressed in tandem.

36. The γδT cell of any one of claims 15-35, further expressing CAR.

37. The γδ T cell of claim 36, wherein the CAR lacks an intracellular signaling domain.

38. The γδ T cell of any one of claims 15-38, wherein the γδ T cell lacks an endogenous gene encoding IL-15.

39. An isolated population of γδ T cells, wherein at least 10% of the population of γδ T cells express recombinant IL-15Rβ.

40. The isolated γδ T cell population of claim 39, wherein at least 50% of the γδ T cell population expresses the recombinant IL-15Rβ.

41. The isolated γδ T cell population of claim 39 or 40, further expressing recombinant IL-15Rα or a fragment thereof.

42. The isolated γδ T cell population of any one of claims 39-41, wherein the IL-15Rα or a fragment thereof is tethered to IL-15 or a variant thereof.

43. The isolated γδ T cell population of any one of claims 39-42, wherein the IL-15Rβ and the IL-15Rα or a fragment thereof are expressed in tandem.

44. The isolated γδ T cell population of claim 43, further comprising a linker between the IL-15Rβ and the IL-15Rα or a fragment thereof.

45. The isolated population of γδ T cells of claim 44, wherein the second linker comprises a cleavable peptide.

46. ​​The isolated γδ T cell population of claim 45, wherein the cleavable peptide is a self-cleaving peptide.

47. The isolated γδ T cell population of claim 46, wherein the self-cleaving peptide is a 2A peptide.

48. The isolated γδ T cell population of claim 47, wherein the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide, or a T2A peptide.

49. The isolated γδ T cell population of claim 48, wherein the 2A peptide is a P2A peptide.

50. The isolated γδT cell population of any one of claims 39-49, further expressing CAR.

51. The isolated γδ T cell population of claim 50, wherein the CAR lacks an intracellular signaling domain.

52. The isolated γδ T cell population of any one of claims 39-51, wherein the γδ T cells lack an endogenous gene encoding IL-15.

53. The isolated γδ T cell population of any one of claims 39-52, further expressing secreted IL-15 or a variant thereof.

54. An isolated population of γδ T cells, wherein at least 10% of the population of γδ T cells express recombinant IL-15Rβ and IL-15 or a variant thereof.

55. The isolated γδ T cell population of claim 54, wherein at least 50% of the γδ T cell population expresses recombinant IL-15Rβ and IL-15 or a variant thereof.

56. The isolated γδ T cell population of any one of claims 54 or 55, wherein the IL-15Rβ and the IL-15 or variant thereof are expressed in tandem.

57. The isolated γδ T cell population of claim 56, further comprising a linker between the IL-15Rβ and the IL-15 receptor or variant thereof.

58. The isolated population of γδ T cells of claim 57, wherein the linker comprises a cleavable peptide.

59. The isolated γδ T cell population of claim 58, wherein the cleavable peptide is a self-cleaving peptide.

60. The isolated γδ T cell population of claim 59, wherein the self-cleaving peptide is a 2A peptide.

61. The isolated γδ T cell population of claim 60, wherein the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide, or a T2A peptide.

62. The isolated γδ T cell population of claim 61, wherein the 2A peptide is a P2A peptide.

63. The isolated γδ T cell population of any one of claims 54-62, further expressing recombinant IL-15Rα or a fragment thereof.

64. The isolated γδ T cell population of claim 63, wherein the fragment of IL-15Rα comprises a soluble fragment.

65. The isolated γδ T cell population of claim 64, wherein the soluble fragment comprises a sushi domain.

66. The isolated γδ T cell population of claim 65, wherein the sushi domain is attached to an Fc domain.

67. The isolated γδ T cell population of any one of claims 63-66, wherein the IL-15Rα or a fragment thereof is tethered to the IL-15 or a variant thereof.

68. The isolated γδ T cell population of any one of claims 63-67, wherein the IL-15Rβ and the IL-15Rα or a fragment thereof are expressed in tandem.

69. The isolated γδ T cell population of claim 68, further comprising a second linker between the IL-15Rβ and the IL-15Rα or a fragment thereof.

70. The isolated γδ T cell population of claim 69, wherein the second linker comprises a cleavable peptide.

71. The isolated γδ T cell population of claim 70, wherein the cleavable peptide is a self-cleaving peptide.

72. The isolated γδ T cell population of claim 71, wherein the self-cleaving peptide is a 2A peptide.

73. The isolated γδ T cell population of claim 72, wherein the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide, or a T2A peptide.

74. The isolated γδ T cell population of claim 73, wherein the 2A peptide is a P2A peptide.

75. The isolated γδ T cell population of any one of claims 63-74, wherein the IL-15Rβ, the IL-15 or a variant thereof, and the recombinant IL-15Rα or a fragment thereof are expressed in tandem.

76. The isolated γδT cell population of any one of claims 54-75, further expressing CAR.

77. An isolated γδ T cell population as described in claim 76, wherein the CAR lacks an intracellular signaling domain.

78. The isolated γδ T cell population of any one of claims 54-77, wherein the γδ T cells lack an endogenous gene encoding IL-15.

79. A method for producing a population of γδ T cells expressing recombinant IL-15Rβ, the method comprising: (a) providing a γδT cell population; as well as (b) engineering the γδ T cell population with a polynucleotide encoding the IL-15Rβ, thereby generating the γδ T cell population expressing the recombinant IL-15Rβ.

80. The method of claim 79, wherein the polynucleotide comprises an IRES operably linked to the IL-15Rβ.

81. The method of claim 79 or 80, further comprising transducing the initial γδ T cell population with a polynucleotide encoding IL-15Rα or a fragment thereof.

82. The method of any one of claims 79-81, wherein the IL-15Rα or fragment thereof is tethered to IL-15 or a variant thereof.

83. The method of any one of claims 79-82, wherein the polynucleotide encodes the IL-15Rβ and the IL-15Rα in tandem.

84. The method of claim 83, wherein the polynucleotide comprises a linker between the IL-15Rβ and the IL-15Rα.

85. The method of claim 84, wherein the linker encodes a cleavable peptide or comprises an IRES.

86. The method of claim 85, wherein the cleavable peptide is a self-cleaving peptide.

87. The method of claim 86, wherein the self-cleaving peptide is a 2A peptide.

88. The method of claim 87, wherein the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide, or a T2A peptide.

89. The method of claim 88, wherein the 2A peptide is a P2A peptide.

90. The method of any one of claims 79-89, further comprising transducing the cell with a polynucleotide encoding a CAR.

91. The method of claim 90, wherein the polynucleotide encodes the CAR and the IL-15Rβ in tandem.

92. The method of claim 91, wherein the polynucleotide comprises a linker between the CAR and the IL-15Rβ.

93. The method of claim 92, wherein the linker encodes a cleavable peptide or comprises an IRES.

94. The method of claim 93, wherein the cleavable peptide is a self-cleaving peptide.

95. The method of claim 94, wherein the self-cleaving peptide is a 2A peptide.

96. The method of claim 95, wherein the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide, or a T2A peptide.

97. The method of claim 96, wherein the 2A peptide is a T2A peptide.

98. A method for producing a population of γδ T cells expressing recombinant IL-15Rβ and IL-15 or a variant thereof, the method comprising: (a) providing a γδT cell population; (b) engineering the γδT cell population with a polynucleotide encoding the IL-15Rβ; as well as (c) engineering the γδ T cell population with a polynucleotide encoding the IL-15 or a variant thereof, thereby generating the γδ T cell population expressing the recombinant IL-15Rβ and the IL-15 or a variant thereof.

99. The method of claim 97, wherein the polynucleotide comprises an IRES operably linked to the IL-15Rβ and / or the IL-15 or variant thereof.

100. The method of claim 98, wherein the polynucleotide encodes the IL-15Rβ and the IL-15 or variant thereof in tandem.

101. The method of claim 100, wherein the polynucleotide comprises a linker between the IL-15Rβ and the IL-15 or variant thereof.

102. The method of claim 101, wherein the linker encodes a cleavable peptide or comprises an IRES.

103. The method of claim 102, wherein the cleavable peptide is a self-cleaving peptide.

104. The method of claim 103, wherein the self-cleaving peptide is a 2A peptide.

105. The method of claim 104, wherein the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide, or a T2A peptide.

106. The method of claim 105, wherein the 2A peptide is a P2A peptide.

107. The method of any one of claims 98-106, further comprising engineering the starting γδ T cell population with a polynucleotide encoding IL-15Rα or a fragment thereof.

108. The method of claim 107, wherein the fragment of IL-15Rα comprises a soluble fragment.

109. The method of claim 108, wherein the soluble fragment comprises a sushi domain.

110. The method of claim 109, wherein the sushi domain is attached to an Fc domain.

111. The method of any one of claims 107-110, wherein the IL-15Rα or fragment thereof is tethered to the IL-15 or variant thereof.

112. The method of any one of claims 107-111, wherein the polynucleotide encodes the IL-15Rβ and the IL-15Rα in tandem.

113. The method of claim 112, wherein the polynucleotide comprises a second linker between the IL-15Rβ and the IL-15Rα.

114. The method of claim 113, wherein the second linker encodes a cleavable peptide or comprises an IRES.

115. The method of claim 114, wherein the cleavable peptide is a self-cleaving peptide.

116. The method of claim 115, wherein the self-cleaving peptide is a 2A peptide.

117. The method of claim 116, wherein the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide, or a T2A peptide.

118. The method of claim 117, wherein the 2A peptide is a P2A peptide.

119. The method of any one of claims 107-118, wherein the polynucleotide encodes the IL-15Rβ, the IL-15 or a variant thereof, and the recombinant IL-15Rα or a fragment thereof in tandem.

120. The method of any one of claims 98-119, further comprising engineering the cell with a polynucleotide encoding a CAR.

121. The method of claim 120, wherein the polynucleotide encodes the CAR and the IL-15Rβ in tandem.

122. The method of claim 121, wherein the polynucleotide comprises a linker between the CAR and the IL-15Rβ.

123. The method of claim 122, wherein the linker encodes a cleavable peptide or comprises an IRES.

124. The method of claim 123, wherein the cleavable peptide is a self-cleaving peptide.

125. The method of claim 124, wherein the self-cleaving peptide is a 2A peptide.

126. The method of claim 125, wherein the 2A peptide is a F2A peptide, an E2A peptide, a P2A peptide, or a T2A peptide.

127. The method of claim 126, wherein the 2A peptide is a T2A peptide.

128. The method of any one of claims 79-127, wherein the method comprises providing a vector comprising the polynucleotide.

129. The method of claim 128, wherein the vector is a viral vector.

130. The method of claim 129, wherein the viral vector is a Retroviridae virus, an adenovirus, a parvovirus, a coronavirus, a rhabdovirus, a paramyxovirus, a picornavirus, an alphavirus, a herpes virus, or a poxvirus.

131. The method of claim 130, wherein the parvoviral viral vector is an AAV vector.

132. The method of claim 130, wherein the viral vector is a Retroviridae viral vector.

133. The method of claim 132, wherein the Retroviridae viral vector is a lentiviral vector.

134. The method of claim 132, wherein the Retroviridae viral vector is an alpha retroviral vector or a gamma retroviral vector.

135. The method of any one of claims 132-134, wherein the Retroviridae viral vector comprises a central polypurine tract, a woodchuck hepatitis virus post-transcriptional regulatory element, a 5'-LTR, an HIV signal sequence, an HIV Psi signal 5'-splice site, a delta-GAG element, a 3'-splice site, and a 3'-self-inactivating LTR.

136. The method of any one of claims 129-135, wherein the viral vector is a pseudotyped viral vector.

137. The method of claim 136, wherein the pseudotyped viral vector is a pseudotyped adenovirus, a pseudotyped parvovirus, a pseudotyped coronavirus, a pseudotyped rhabdovirus, a pseudotyped paramyxovirus, a pseudotyped picornavirus, a pseudotyped alphavirus, a pseudotyped herpesvirus, a pseudotyped poxvirus, or a pseudotyped retroviridae virus.

138. The method of claim 137, wherein the pseudotyped viral vector is a lentiviral vector.

139. The method of any one of claims 136-138, wherein the pseudotyped viral vector comprises one or more envelope proteins from a virus selected from the group consisting of vesicular stomatitis virus VSV, RD114 virus, MLV, FeLV, VEE, HFV, WDSV, SFV, rabies virus, ALV, BIV, BLV, EBV, CAEV, SNV, ChTLV, STLV, MPMV, SMRV, RAV, FuSV, MH2, AEV, AMV, avian sarcoma virus CT10, and EIAV.

140. The method of claim 139, wherein the pseudotyped viral vector comprises VSV-G envelope protein.

141. The method of any one of claims 79-140, further comprising culturing the initial γδ T cell population in the presence of exogenous IL-2 and / or IL-15.

142. The method of any one of claims 79-141, wherein at least 10% of the γδ T cell population expresses the IL-15Rβ.

143. The method of claim 142, wherein at least 50% of the γδ T cell population expresses the IL-15Rβ.

144. A method for expanding γδT cells, the method comprising: (a) providing a population of γδT cells expressing IL-15Rβ; as well as (b) culturing the γδ T cell population in the presence of exogenous IL-2 and / or IL-15 or variants thereof.

145. The method of claim 144, wherein the γδ T cell population further expresses recombinant IL-15Rα or a fragment thereof.

146. The method of any one of claims 107-143 and 145, wherein the IL-15Rα or fragment thereof is tethered to IL-15 or a variant thereof.

147. A method for expanding γδT cells, the method comprising: (a) providing a population of γδ T cells expressing IL-15Rβ and IL-15 or a variant thereof; as well as (b) culturing the γδ T cells, wherein the IL-15 or a variant thereof expands the γδ T cell population.

148. The method of claim 147, further comprising culturing the γδ T cell population in the presence of exogenous IL-2.

149. The method of claim 147 or 148, wherein the γδ T cell population further expresses recombinant IL-15Rα or a fragment thereof.

150. The method of claim 149, wherein the fragment of IL-15Rα comprises a soluble fragment.

151. The method of claim 151, wherein the soluble fragment comprises a sushi domain.

152. The method of claim 152, wherein the sushi domain is attached to an Fc domain.

153. The method of any one of claims 149-152, wherein the IL-15Rα or fragment thereof is tethered to IL-15 or a variant thereof.

Citation Information

Patent Citations

  • Process for amplifying, detecting, and / or-cloning nucleic acid sequences

    US4683195A

  • RNA export element

    US6136597A

  • Cell line of lymphocytes comprising gamma-delta T cells, composition and production method thereof

    US9499788B2

  • Il-15ralpha sushi domain as a selective and potent enhancer of il-15 action through il-15rbeta / gamma, and hyperagonist (ilralpha sushi-il 15) fusion proteins

    WO2007046006A2

  • Methods for the production of TCR gamma delta + t cells

    WO2016198480A1